<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Genes (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Genes (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2104</journal-id><journal-id journal-id-type="pmc-domain">genes</journal-id><journal-id journal-id-type="publisher-id">genes</journal-id><journal-title-group><journal-title>Genes</journal-title></journal-title-group><issn pub-type="epub">2073-4425</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11353732</article-id><article-id pub-id-type="pmcid-ver">PMC11353732.1</article-id><article-id pub-id-type="pmcaid">11353732</article-id><article-id pub-id-type="pmcaiid">11353732</article-id><article-id pub-id-type="pmid">39202335</article-id><article-id pub-id-type="doi">10.3390/genes15080975</article-id><article-id pub-id-type="publisher-id">genes-15-00975</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Simulated Microgravity Alters Gene Regulation Linked to Immunity and Cardiovascular Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tahimic</surname><given-names initials="CGT">Candice G. T.</given-names></name><xref rid="af1-genes-15-00975" ref-type="aff">1</xref><xref rid="af2-genes-15-00975" ref-type="aff">2</xref><xref rid="c1-genes-15-00975" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5415-828X</contrib-id><name name-style="western"><surname>Steczina</surname><given-names initials="S">Sonette</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-genes-15-00975" ref-type="aff">2</xref><xref rid="af3-genes-15-00975" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7822-7040</contrib-id><name name-style="western"><surname>Sebastian</surname><given-names initials="A">Aimy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-genes-15-00975" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1605-3193</contrib-id><name name-style="western"><surname>Hum</surname><given-names initials="NR">Nicholas R.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af4-genes-15-00975" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abegaz</surname><given-names initials="M">Metadel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af2-genes-15-00975" ref-type="aff">2</xref><xref rid="af3-genes-15-00975" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Terada</surname><given-names initials="M">Masahiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af2-genes-15-00975" ref-type="aff">2</xref><xref rid="af5-genes-15-00975" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cimini</surname><given-names initials="M">Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af6-genes-15-00975" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goukassian</surname><given-names initials="DA">David A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af7-genes-15-00975" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schreurs</surname><given-names initials="AS">Ann-Sofie</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-genes-15-00975" ref-type="aff">2</xref><xref rid="af5-genes-15-00975" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoban-Higgins</surname><given-names initials="TM">Tana M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af8-genes-15-00975" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fuller</surname><given-names initials="CA">Charles A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af8-genes-15-00975" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9546-5561</contrib-id><name name-style="western"><surname>Loots</surname><given-names initials="GG">Gabriela G.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af4-genes-15-00975" ref-type="aff">4</xref><xref rid="af9-genes-15-00975" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Globus</surname><given-names initials="RK">Ruth K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-genes-15-00975" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shirazi-Fard</surname><given-names initials="Y">Yasaman</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-genes-15-00975" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Lange</surname><given-names initials="S">Sigrun</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Inal</surname><given-names initials="JM">Jameel M.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-genes-15-00975"><label>1</label>Department of Biology, University of North Florida, Jacksonville, FL 32224, USA</aff><aff id="af2-genes-15-00975"><label>2</label>Space Biosciences Division, NASA Ames Research Center, Moffett Field, CA 94035, USA<email>metadel.f.abegaz@gmail.com</email> (M.A.); <email>yasaman.shirazi-fard@nasa.gov</email> (Y.S.)</aff><aff id="af3-genes-15-00975"><label>3</label>Blue Marble Space Institute of Science, Seattle, WA 98104, USA</aff><aff id="af4-genes-15-00975"><label>4</label>Lawrence Livermore National Laboratory, Livermore, CA 94550, USA<email>gloots@ucdavis.edu</email> (G.G.L.)</aff><aff id="af5-genes-15-00975"><label>5</label>Universities Space Research Association, Washington, DC 20024, USA</aff><aff id="af6-genes-15-00975"><label>6</label>Temple University School of Medicine, Philadelphia, PA 19140, USA; <email>maria.cimini@temple.edu</email></aff><aff id="af7-genes-15-00975"><label>7</label>Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; <email>david.goukassian@mssm.edu</email></aff><aff id="af8-genes-15-00975"><label>8</label>Department of Neurobiology, Physiology and Behavior, University of California Davis, Davis, CA 95616, USA</aff><aff id="af9-genes-15-00975"><label>9</label>Department of Orthopedic Surgery, University of California Davis Health, Sacramento, CA 95817, USA</aff><author-notes><corresp id="c1-genes-15-00975"><label>*</label>Correspondence: <email>c.tahimic@unf.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>15</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">469530</issue-id><elocation-id>975</elocation-id><history><date date-type="received"><day>29</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>18</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>29</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-02 08:25:24.830"><day>02</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="genes-15-00975.pdf"/><abstract><p>Microgravity exposure induces a cephalad fluid shift and an overall reduction in physical activity levels which can lead to cardiovascular deconditioning in the absence of countermeasures. Future spaceflight missions will expose crew to extended periods of microgravity among other stressors, the effects of which on cardiovascular health are not fully known. In this study, we determined cardiac responses to extended microgravity exposure using the rat hindlimb unloading (HU) model. We hypothesized that exposure to prolonged simulated microgravity and subsequent recovery would lead to increased oxidative damage and altered expression of genes involved in the oxidative response. To test this hypothesis, we examined hearts of male (three and nine months of age) and female (3 months of age) Long&#8211;Evans rats that underwent HU for various durations up to 90 days and reambulated up to 90 days post-HU. Results indicate sex-dependent changes in oxidative damage marker 8-hydroxydeoxyguanosine (8-OHdG) and antioxidant gene expression in left ventricular tissue. Three-month-old females displayed elevated 8-OHdG levels after 14 days of HU while age-matched males did not. In nine-month-old males, there were no differences in 8-OHdG levels between HU and normally loaded control males at any of the timepoints tested following HU. RNAseq analysis of left ventricular tissue from nine-month-old males after 14 days of HU revealed upregulation of pathways involved in pro-inflammatory signaling, immune cell activation and differential expression of genes associated with cardiovascular disease progression. Taken together, these findings provide a rationale for targeting antioxidant and immune pathways and that sex differences should be taken into account in the development of countermeasures to maintain cardiovascular health in space.</p></abstract><kwd-group><kwd>hindlimb unloading</kwd><kwd>microgravity</kwd><kwd>cardiovascular system</kwd><kwd>immune response</kwd><kwd>transcriptomics</kwd></kwd-group><funding-group><award-group><funding-source>NASA Human Research Program Human Health Countermeasures (HRP HHC)</funding-source><award-id>NNJ14ZSA001N-FLAGSHIP</award-id><award-id>NNJ13ZSA002N-FLAGSHIP</award-id><award-id>NNX13AD94G</award-id></award-group><award-group><funding-source>NASA Space Biology Postdoctoral Program (NPP)</funding-source></award-group><award-group><funding-source>U.S. Department of Energy by Lawrence Livermore National Laboratory</funding-source><award-id>DE-AC52-07NA27344</award-id></award-group><funding-statement>This work was funded by grants from the NASA Human Research Program Human Health Countermeasures (HRP HHC) NNJ14ZSA001N-FLAGSHIP and NNJ13ZSA002N-FLAGSHIP (both to R.K.G.) and NNX13AD94G to C.A.F. A. Schreurs and M.T. were supported by fellowships from the NASA Space Biology Postdoctoral Program (NPP). Work by G.G.L., N.R.H., and A. Sebastian were performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-genes-15-00975"><title>1. Introduction</title><p>Spaceflight leads to cardiovascular deconditioning in the absence of mitigation strategies. Cardiovascular changes in response to spaceflight are attributed to altered microgravity levels and the ensuing cephalad fluid shift [<xref rid="B1-genes-15-00975" ref-type="bibr">1</xref>]. Overall reductions in physical activity and other factors such as nutritional changes, elevated CO<sub>2</sub> levels, and a demanding workload also may be contributing factors. Some of the reported cardiovascular changes caused by exposure to the spaceflight environment include reductions in left ventricular mass [<xref rid="B2-genes-15-00975" ref-type="bibr">2</xref>,<xref rid="B3-genes-15-00975" ref-type="bibr">3</xref>], transient atrial distension [<xref rid="B4-genes-15-00975" ref-type="bibr">4</xref>], and hypovolemia [<xref rid="B5-genes-15-00975" ref-type="bibr">5</xref>]. Stagnant or retrograde venous flow as well as thrombosis have been observed in crew during flight [<xref rid="B6-genes-15-00975" ref-type="bibr">6</xref>]. Heart rhythm disturbances postflight also have been reported [<xref rid="B7-genes-15-00975" ref-type="bibr">7</xref>]. Orthostatic intolerance [<xref rid="B8-genes-15-00975" ref-type="bibr">8</xref>] and stiffer carotid arteries [<xref rid="B9-genes-15-00975" ref-type="bibr">9</xref>] have also been observed in crew upon return to Earth. Crew on exploration-class missions (e.g., trip to Mars) will experience prolonged periods of microgravity and exposure to low doses of space radiation given current spacecraft shielding designs. Therefore, it is important to understand the cardiovascular responses to long-duration spaceflight to mitigate potential health risks.</p><p>The rodent hindlimb unloading (HU) model [<xref rid="B10-genes-15-00975" ref-type="bibr">10</xref>,<xref rid="B11-genes-15-00975" ref-type="bibr">11</xref>] has been used to gain insights into some aspects of human cardiovascular responses to microgravity and cephalad fluid shifts. HU for four weeks in rats resulted in decreased left ventricular mass and volume [<xref rid="B12-genes-15-00975" ref-type="bibr">12</xref>], consistent with findings from a number of bed rest studies [<xref rid="B2-genes-15-00975" ref-type="bibr">2</xref>,<xref rid="B13-genes-15-00975" ref-type="bibr">13</xref>,<xref rid="B14-genes-15-00975" ref-type="bibr">14</xref>,<xref rid="B15-genes-15-00975" ref-type="bibr">15</xref>,<xref rid="B16-genes-15-00975" ref-type="bibr">16</xref>] and from spaceflight [<xref rid="B3-genes-15-00975" ref-type="bibr">3</xref>]. Two weeks of HU in rats perturbs day&#8211;night blood pressure (BP) and heart rate regulation [<xref rid="B17-genes-15-00975" ref-type="bibr">17</xref>]. Compared to baseline (pre-HU) values, HU generally led to increased systolic and diastolic BP during both day and night cycles, whereas heart rate was increased during the day but not at night. Some of these HU findings could also have been confounded by other factors such as social isolation and restraint stress [<xref rid="B17-genes-15-00975" ref-type="bibr">17</xref>]. In addition, arrhythmias and aberrant intracellular Ca<sup>2+</sup> signaling have been observed in mice that underwent HU (26&#8211;56 days) [<xref rid="B18-genes-15-00975" ref-type="bibr">18</xref>]. Changes in redox balance have also been reported. For example, hearts from male Sprague&#8211;Dawley rats that underwent two weeks of HU displayed increased levels of malondialdehyde, a lipid peroxidation marker [<xref rid="B19-genes-15-00975" ref-type="bibr">19</xref>].</p><p>Currently, there is limited information regarding the effects of long-duration spaceflight on the human cardiovascular system at time scales relevant to interplanetary missions (&gt;2 years). In addition, the effects of age, sex, duration of exposure, and long-term recovery on cardiovascular outcomes are not well established. Hence, the goals of our study are to (1) determine the impact of sex, age, duration of exposure, and recovery on oxidative stress responses to microgravity and (2) define underlying molecular mechanisms. We hypothesized that exposure to simulated microgravity and the ensuing recovery would lead to changes in redox balance and the expression of select genes including those that play a role in oxidative stress responses. To test this hypothesis, we examined hearts from male and female rats that underwent hindlimb unloading (HU) for various durations (up to 90 days) and those that underwent reambulation after 90 days of HU. To achieve this, we assessed DNA oxidative damage markers and select transcripts, and performed RNAseq analysis of cardiac tissue.</p></sec><sec id="sec2-genes-15-00975"><title>2. Materials and Methods</title><sec id="sec2dot1-genes-15-00975"><title>2.1. Animals and Experiment Design</title><p>Animal experiments were carried out in accordance with the recommendations of Guide for the Care and Use of Laboratory Animals, 8th edition. All animal experiments were conducted with prior approval from the UC Davis Institutional Animal Care and Use Committee (IACUC). Female and male Long&#8211;Evans rats (Taconic) were selected for this study. Animals were group-housed in standard vivarium cages until the onset of HU. A group of females and males (referred to as &#8220;young&#8221;) underwent HU at three months of age, while a group of retired male breeders (referred to as &#8220;older males&#8221;) began HU at nine months of age. Normally loaded (NL) controls were individually housed in standard vivarium cages. Animals were suspended onto the pulley apparatus via orthopedic traction tape as described previously [<xref rid="B11-genes-15-00975" ref-type="bibr">11</xref>]. NL controls were handled the same way as the HU animals except for the actual attachment of traction tape and tail suspension. HU was conducted for either 14 days or 90 days. A subset of nine-month-old (older) males that underwent HU for 90 days were then released from the suspension apparatus to reambulate normally (Reloading, Rel) for 90 days. All animals were supplied with standard rodent laboratory chow (Purina, St. Louis, MO, USA) and water ad libitum. Enrichment consisted of Diamond Twists paper sticks (Harlan, Indianapolis, IN, USA) and I-Chews (Newco, Hayward, CA, USA) and replenished as needed. Room temperature was maintained within a range of 20&#8211;26 &#176;C with a 12-h light and 12-h dark cycle. After the designated duration of HU, animals were euthanized via isoflurane overdose followed by exsanguination and decapitation. Tissues were collected shortly thereafter. Hearts were bisected, flash-frozen in liquid nitrogen, and stored at &#8722;80 &#176;C until processing. Refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S1</xref> for the sample sizes of the experiment groups included in this study. Young male and female, 90 day HU, and recovery groups were not included in the study either due to insufficient sample sizes or unavailability of appropriately processed samples.</p></sec><sec id="sec2dot2-genes-15-00975"><title>2.2. Processing of Frozen Heart Samples</title><p>Frozen hearts were retrieved from &#8722;80 &#176;C storage and placed on a metal platform that was pre-chilled with liquid nitrogen. Left ventricular tissue was excised from the anterior to posterior ends (apex) of the heart. The excised left ventricular tissue was further cut into thirds (anterior, middle, and posterior). The anterior and posterior thirds were processed for DNA and RNA extraction, respectively. Samples were excluded from analyses if anatomical landmarks could not be conclusively identified for isolation of left ventricular tissue.</p></sec><sec id="sec2dot3-genes-15-00975"><title>2.3. RNA Extraction from Cardiac Tissue</title><p>Total RNA was extracted from frozen left ventricular tissue using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Germantown, MD, USA) according to manufacturer&#8217;s protocol. RNA concentration was determined using NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA, USA), and purity was determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples showing an RNA integrity number (RIN) &gt; 8 were used for RNA sequencing and quantitative polymerase chain reaction (qPCR).</p></sec><sec id="sec2dot4-genes-15-00975"><title>2.4. cDNA Synthesis and qPCR</title><p>First-strand DNA was synthesized from total RNA as follows. A total of 450 ng of RNA was used for a 30 uL first strand synthesis. Briefly, 1.5 uL of random hexamers (Invitrogen, Waltham, MA, USA, Cat# N8080127), 1.5 &#956;L dNTPs (Qiagen, Cat# 1005631), and 12 &#956;L of water were mixed, incubated at 65 &#176;C for 5 min, and immediately chilled on ice. A solution-containing 3 &#956;L RNase-free water, 6 &#956;L 5&#215; first strand buffer (Invitrogen, Cat# Y02321), 3 &#956;L DTT (Invitrogen, Cat# Y00147), and 1.5 &#956;L RNase Out (Invitrogen, Cat# 100000840) was added to the abovementioned mix and then incubated at 37 &#176;C for 2 min. Then 1.5 &#956;L of Moloney Murine Leukemia Virus (MMLV) reverse transcriptase (200 U/&#956;L, Invitrogen, Waltham, MA, USA, Cat# 28025013) was added to the resulting solution and incubated as follows: 25 &#176;C for 10 min, 37 &#176;C for 50 min, and 70 &#176;C for 15 min. All incubation steps were performed using a TC-312 thermocycler (Techne, Vernon Hills, IL, USA). First-strand DNA was stored at &#8722;80 &#176;C until use for qPCR using the Taqman system. Multiplex PCR reactions were set up to measure both genes of interest and housekeeping gene expression in the same well of a 384-well plate. A premade gene expression master mix (Taqman, LifeTechnologies, Waltham, MA, USA, Cat# 4369016) was utilized, and each reaction was completed in duplicate. FAM-labeled Taqman probes (LifeTechnologies, Waltham, MA, USA) were used for the following genes of interest: nuclear factor, erythroid 2-like 2 (<italic toggle="yes">Nfe2l2,</italic> Rn00582415_m1), superoxide dismutase 1 (<italic toggle="yes">Sod1</italic>, Rn00566938_m1), superoxide dismutase 2 (<italic toggle="yes">Sod2</italic>, Rn00690588_g1), and sirtuin 1 (<italic toggle="yes">Sirt1</italic>, Rn01428096_m1). VIC-labeled ribosomal protein L19 (<italic toggle="yes">Rpl19</italic>, Rn00821265_g1) was used as housekeeping gene. qPCR was performed on a QuantStudio 6 Flex Real-Time PCR instrument (Applied Biosystems, Waltham, MA, USA). The relative gene expression levels for HU groups relative to age- and sex-matched controls were determined by the &#916;&#916;Ct method and reported as fold change.</p></sec><sec id="sec2dot5-genes-15-00975"><title>2.5. 8-Hydroxydeoxyguanosine (8-OHdG) Assay</title><p>Total DNA was extracted from frozen left ventricular tissue using the DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer&#8217;s protocol. Quantification of 8-OHdG was performed using OxiSelect&#8482; Oxidative DNA Damage ELISA Kit (Cell Biolabs Inc., San Diego, CA, USA, Cat# STA-320) following manufacturer&#8217;s specifications. Enzyme reaction/absorbance was measured using a Spectra Max 250 (Molecular Devices, San Jose, CA, USA) and Softmax Pro 5 software.</p></sec><sec id="sec2dot6-genes-15-00975"><title>2.6. RNA Sequencing and Bioinformatics Analysis</title><p>Poly(A)+-enriched cDNA libraries were prepared using the Illumina TruSeq RNA Library Prep kit (Illumina Inc., Hayward, CA, USA) and sequenced using Illumina NextSeq 550 (Illumina Inc., Hayward, CA, USA) instrument to generate 75 bp single-end reads. Sequencing data quality was checked using FastQC (version 0.11.5) software. Subsequently, reads were mapped to the rat reference genome (rn6) using STAR (version 2.6.0c). Then, a matrix of read counts per gene was generated using &#8220;featureCounts&#8221; from the Rsubread package (version 1.30.5). Genes with low expression values were filtered from downstream analysis by requiring more than 5 reads in at least 6 samples for each gene. Subsequently, between-sample normalization was performed using EDASeq (version 2.16.0). One sample from each group had to be excluded from analysis due to technical issues. Hence, 6 samples per group were used for the succeeding analysis. RUVseq (version 1.16.0) [RUVs with k = 4] was used to estimate the factors of unwanted variation. Genes differentially expressed between HU and control samples were identified using DESeq2 (version 1.22.2), controlling for factors of unwanted variation. Hierarchical clustering analysis was performed and heat maps generated using Morpheus, with Pearson method selected [<xref rid="B20-genes-15-00975" ref-type="bibr">20</xref>]. RStudio analysis software (Version 1.1.419), together with ggplot2 (version 3.1.1), ggrepel (version 0.8.0), and Bioconductor (DESeq2 version 1.22.2) packages, were used to obtain principal component analysis plots. For gene enrichment analysis, differentially expressed genes meeting a log2 fold change cut-off of &gt;0.3 or &lt;&#8722;0.3 and an adjusted <italic toggle="yes">p</italic>-value &lt; 0.05 were input into Toppfun [<xref rid="B21-genes-15-00975" ref-type="bibr">21</xref>,<xref rid="B22-genes-15-00975" ref-type="bibr">22</xref>]. Toppfun was used to assess functional enrichment of DEGs based on ontologies, gene family, phenotype (human disease), and pharmacome (drug&#8211;gene associations). Of the 125 differentially expressed genes (DEGs), 121 matched the contents of the Toppfun database and were therefore included in the list for gene enrichment analysis. The DEGs that had no match in the Toppfun database were <italic toggle="yes">Clec4a1</italic>, <italic toggle="yes">Lilrb3l</italic>, <italic toggle="yes">Fcna</italic>, and <italic toggle="yes">Mill1</italic>. Gene enrichment analysis was performed at a false discovery rate (FDR, Benjamini Hochberg) of &lt;0.05 and a gene limit of 2 or greater. GO Terms were plotted for visualization using the matplotlib.pyplot, seaborn, and pandas packages run in Google Colaboratory (Python ver 3.10).</p></sec><sec id="sec2dot7-genes-15-00975"><title>2.7. Statistical Analysis</title><p>Equivalence of variance was first evaluated by Levene&#8217;s test. Once equal variance was confirmed, a <italic toggle="yes">t</italic>-test was performed to compare HU and matched control groups. This study involved an extended sampling period (3 years). To minimize batch effects, we compared HU and the matched controls for any given sex and timepoint since these groups were collected within the same period. Specifically, any HU group and its normally loaded control group (e.g., young male 14 day HU and NL groups) were euthanized on the same day or a day apart. Comparisons were not made across timepoints, sexes, or ages. Statistical analyses were performed using JMP software version 13.1.0 (SAS Institute Inc., Cary, NC, USA). Data shown are mean +/&#8722; S.D.</p></sec></sec><sec sec-type="results" id="sec3-genes-15-00975"><title>3. Results</title><p>In this study, we made use of the rodent HU model to gain insight on the effects of microgravity exposure on molecular signatures of the heart. With the exception of the 14-day HU young females, all HU groups had lower body weights versus age- and sex-matched controls (<xref rid="genes-15-00975-f001" ref-type="fig">Figure 1</xref>), consistent with previous reports [<xref rid="B23-genes-15-00975" ref-type="bibr">23</xref>,<xref rid="B24-genes-15-00975" ref-type="bibr">24</xref>,<xref rid="B25-genes-15-00975" ref-type="bibr">25</xref>]. Weight loss in HU groups of older males was transient, with body weights of NL and HU groups being comparable after 90 days of reambulation. Due to the modest decrease in body weight (10&#8211;13%), we do not expect weight loss to be a major confounding factor in other experimental outcomes.</p><p>To determine whether simulated microgravity leads to alterations in redox balance in cardiac tissue, we measured levels of 8-hydroxydeoxyguanosine (8-OHdG) in left ventricular tissue (<xref rid="genes-15-00975-f002" ref-type="fig">Figure 2</xref>). 8-OHdG is a marker for oxidative damage to DNA. Young females after 14 days of HU displayed a modest yet statistically significant increase in 8-OHdG levels (33.2%) compared to age- and sex-matched controls. At 14 days of HU, no differences were observed between HU and control groups in young and older males. Older males at 90 days of HU did not exhibit any significant difference in 8-OHdG levels versus corresponding controls. We further hypothesized that reloading will lead to increased oxidative damage to hearts due to altered fluid distribution and increased functional demand on the heart. Hence, we examined 8-OHdG levels at an earlier timepoint of reambulation (7 days) where we found no differences in 8-OHdG levels in older males that underwent normal reambulation after 90 days of HU relative to controls.</p><p>To further assess any changes in key molecular determinants of redox balance, we measured gene expression levels of select antioxidant genes (<italic toggle="yes">Sod1</italic> and <italic toggle="yes">Sod2</italic>) as well as a master transcriptional regulator of the antioxidant response, <italic toggle="yes">Nfe2l2</italic> (<xref rid="genes-15-00975-f003" ref-type="fig">Figure 3</xref>A&#8211;C). In addition, we examined the gene expression of <italic toggle="yes">Sirt1</italic>, a marker of cellular senescence and oxidative stress also known to impact longevity [<xref rid="B26-genes-15-00975" ref-type="bibr">26</xref>,<xref rid="B27-genes-15-00975" ref-type="bibr">27</xref>] (<xref rid="genes-15-00975-f003" ref-type="fig">Figure 3</xref>D). Compared to sex- and age-matched controls, young females that underwent 14 days of HU did not show any changes in gene expression for any of the four genes tested. Young males at the same timepoint showed a modest downregulation of <italic toggle="yes">Nfe2l2</italic> (<xref rid="genes-15-00975-f003" ref-type="fig">Figure 3</xref>A) as well as upregulation of <italic toggle="yes">Sod1</italic> and <italic toggle="yes">Sod2</italic> (<xref rid="genes-15-00975-f003" ref-type="fig">Figure 3</xref>B and 3C respectively), but no change in <italic toggle="yes">Sirt1</italic> expression (<xref rid="genes-15-00975-f003" ref-type="fig">Figure 3</xref>D). In older males, <italic toggle="yes">Nfe2l2</italic> was downregulated at 14 days of HU, while there were no changes in <italic toggle="yes">Sod1</italic>, <italic toggle="yes">Sod2,</italic> or <italic toggle="yes">Sirt1</italic> expression. The downregulation of <italic toggle="yes">Nfe2l2</italic> expression in older males persisted at 90 days of HU. After a 90-day reambulation period, this pattern was reversed, with HU groups showing upregulated expression of <italic toggle="yes">Nfe2l2</italic> and <italic toggle="yes">Sirt1</italic> relative to controls.</p><p>We reasoned that identifying the molecular signature of the early adaptation of cardiac tissue to HU will allow us to link early changes in gene expression and biological pathways to later cardiac outcomes. We therefore conducted transcriptomic analysis (RNAseq) of tissue from the left ventricle in older (nine-month-old) males and their corresponding controls. We selected nine-month-old males for analysis (samples were not available for females of similar age) over the other three-month-old groups. Principal component analysis (PCA) and hierarchical clustering generally indicated clustering by treatment group (<xref rid="genes-15-00975-f004" ref-type="fig">Figure 4</xref> and <xref rid="genes-15-00975-f005" ref-type="fig">Figure 5</xref> respectively). A total of 125 genes were differentially expressed in the HU group relative to controls. Of these, 48 were upregulated and 77 were downregulated (<xref rid="genes-15-00975-t001" ref-type="table">Table 1</xref>). The top 10 upregulated and downregulated genes included a number of immune-related genes such as <italic toggle="yes">Tlr8</italic> and the macrophage/monocyte markers <italic toggle="yes">CD68</italic> and <italic toggle="yes">CD163</italic> as well as two circadian clock-related genes, <italic toggle="yes">Per3</italic> and <italic toggle="yes">Arntl</italic> (<xref rid="genes-15-00975-f006" ref-type="fig">Figure 6</xref>). Fifteen of these DEG&#8217;s were cluster-of-differentiation (CD) molecules belonging to the C-type lectin domain family, while 6 were LY6/PLAUR domain-containing members of the complement gene family (<xref rid="genes-15-00975-t002" ref-type="table">Table 2</xref>). <italic toggle="yes">Nfe2l2</italic> did not appear as a downregulated gene in the 14D HU hearts of older males based on RNAseq despite the observed decrease (although modest) in transcript levels by qPCR analysis (<xref rid="genes-15-00975-f003" ref-type="fig">Figure 3</xref>A, <xref rid="genes-15-00975-t001" ref-type="table">Table 1</xref>). This is likely due to differences in the normalization methods for the two assays.</p><p>Gene enrichment analysis of DEGs that met the FDR threshold revealed a predominance of immune-related processes including macrophage activation and complement activation. Further, circadian signaling, vesicle-mediated transport, and redox signaling were differentially enriched (<xref rid="genes-15-00975-f007" ref-type="fig">Figure 7</xref>; refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S2</xref> for full list). Gene enrichment analysis for disease phenotypes using Toppfun [<xref rid="B21-genes-15-00975" ref-type="bibr">21</xref>,<xref rid="B22-genes-15-00975" ref-type="bibr">22</xref>] also revealed enrichment of a subset of DEGs linked to cardiovascular disease (CVD), immune dysfunction, neurovascular disease, cancer, metabolic disease, and sleep disorders. Cardiovascular pathologies represented include hypertensive disease, myocardial infarction, and heart failure. Immune disorders include complement deficiency and the autoimmune disease lupus erythematosus (<xref rid="genes-15-00975-t003" ref-type="table">Table 3</xref>; refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S3</xref> for full list). Consistent with the human disease phenotype findings, 24 DEGs were associated with the anti-bradycardia drug isoproterenol, a non-selective &#946; adrenergic receptor agonist. In addition, a number of DEGs were associated with anti-hypertensive drugs losartan and valsartan, both angiotensin receptor blockers. A subset of DEGs also were associated with simvastatin (anticholesterolemic), doxorubicin (cancer treatment), rosiglitazone (antidiabetic), and melatonin (sleeping aid) (<xref rid="genes-15-00975-t004" ref-type="table">Table 4</xref>; refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S4</xref> for full list).</p></sec><sec sec-type="discussion" id="sec4-genes-15-00975"><title>4. Discussion</title><p>The objective of this study was to determine the impact of simulated microgravity on redox signaling in the heart and the overall transcriptomic landscape. Our findings from a rat hindlimb unloading (HU) model for cephalad fluid shift and microgravity exposure suggest sex and age differences in oxidative stress responses. Young males displayed upregulation in the expression of the antioxidants <italic toggle="yes">Sod1</italic> and <italic toggle="yes">Sod2</italic>, and a decrease in <italic toggle="yes">Nfe2l2</italic> expression, with no changes in 8-OHdG levels. On the other hand, increased levels of the DNA oxidative marker 8-OHdG was observed in females that underwent 14 days of HU with no changes in the expression levels of the redox signaling-related genes examined. One interpretation of our findings is that during short-term HU, young males mitigate oxidative damage more effectively than young females. Alternatively, it is possible that the kinetics of the emergence and repair of oxidative damage are sexually dimorphic. It is also unclear whether sex differences in oxidative stress responses persist due to unavailability of samples at later timepoints. Further, short-term HU in older males does not appear to enhance oxidative damage. Although not statistically significant, there was a trend toward increased 8-OHdG in the older males that underwent 90 days of HU compared to controls. We cannot rule out the possibility that long-duration HU can increase oxidative damage in the hearts of older males due to the small sample size available to perform the 8-OHdG assay in these groups. At 14 days of HU, older males exhibited a downregulation of <italic toggle="yes">Nfe2l2</italic> expression, while 8-OHdG levels were not different between HU and controls. The persistent downregulation of <italic toggle="yes">Nfe2l2</italic> at this timepoint is consistent with the observed trend towards increased oxidative damage during prolonged HU. A 90 day reambulation period after prolonged HU of 90 days led to upregulated <italic toggle="yes">Nfe2l2</italic> and <italic toggle="yes">Sirt1</italic> expression. It is possible that upregulation of <italic toggle="yes">Nfe2l2</italic> and <italic toggle="yes">Sirt1</italic> may be one of the underlying mechanisms by which the heart can recover from extended durations of HU. We recognize the extended time period for the conduct of the HU experiments and varying sample sizes across groups as limitations of our study. Specifically, the interpretation of the results from the 8-OHdG and qPCR assays which were performed on multiple HU groups and their corresponding NL controls merits further study. Consistent with our findings, another group has reported that HU elicits an antioxidant response. In the hearts of 6-month-old mice, HU led to time-dependent increases in the oxidation of glutathione to glutathione disulfide, an indicator of oxidative damage [<xref rid="B28-genes-15-00975" ref-type="bibr">28</xref>]. Taken together, our findings and those of others support the use of antioxidant-based countermeasures for extended duration spaceflight.</p><p>RNAseq results indicate that 14 days of HU in older males leads to enrichment of processes involved in the immune response, including complement activation and inflammation (<xref rid="genes-15-00975-f007" ref-type="fig">Figure 7</xref>, <xref rid="app1-genes-15-00975" ref-type="app">Table S2</xref>). Complement activation, a component of innate immunity, is a mechanism by which the host defends against microbial infections. Studies in the last decade have revealed a role for the complement system in recognizing damaged host cells and coordinating with other elements of the immune response to achieve resolution to injury [<xref rid="B29-genes-15-00975" ref-type="bibr">29</xref>,<xref rid="B30-genes-15-00975" ref-type="bibr">30</xref>,<xref rid="B31-genes-15-00975" ref-type="bibr">31</xref>]. Dysregulated complement responses have been linked to autoimmune disease [<xref rid="B32-genes-15-00975" ref-type="bibr">32</xref>] as well as poor outcomes in patients with cardiovascular disease [<xref rid="B33-genes-15-00975" ref-type="bibr">33</xref>,<xref rid="B34-genes-15-00975" ref-type="bibr">34</xref>,<xref rid="B35-genes-15-00975" ref-type="bibr">35</xref>] and related animal models [<xref rid="B36-genes-15-00975" ref-type="bibr">36</xref>,<xref rid="B37-genes-15-00975" ref-type="bibr">37</xref>]. Our results indicate upregulation of several complement genes. These include <italic toggle="yes">C1qa</italic>, <italic toggle="yes">C1qb</italic>, and <italic toggle="yes">C1qc</italic>, all components of the membrane attack complex, as well as <italic toggle="yes">C5ar1</italic>, the receptor for the complement anaphylatoxin 5a, which can stimulate immune cells in myocardial infarct models [<xref rid="B29-genes-15-00975" ref-type="bibr">29</xref>,<xref rid="B36-genes-15-00975" ref-type="bibr">36</xref>,<xref rid="B37-genes-15-00975" ref-type="bibr">37</xref>] (<xref rid="genes-15-00975-t001" ref-type="table">Table 1</xref>). The implication of upregulated complement response in cardiac tissue during simulated microgravity requires further study given the emerging role of the complement pathway in the development of cardiovascular disease [<xref rid="B37-genes-15-00975" ref-type="bibr">37</xref>,<xref rid="B38-genes-15-00975" ref-type="bibr">38</xref>]. Interestingly, in International Space Station (ISS) crew, elements of the complement response were found to be modestly increased within a week of return to Earth relative to pre-flight values [<xref rid="B39-genes-15-00975" ref-type="bibr">39</xref>]. However, the impact of actual flight on complement responses could not be evaluated, since no in-flight measures were reported in the said study.</p><p>The underlying bases for the observed upregulation of complement genes in HU hearts is unclear. In Earth-based cardiovascular disease, altered fluid distribution and pressure changes can give rise to injury of cardiac tissue and therefore may play a role in the upregulated complement response seen in this rodent model for microgravity-induced fluid shifts. Complement activation also can occur as a response to pathogens or their constituents. Hence, another possibility that requires further study is the role of gut permeability in promoting a complement response during simulated microgravity. HU has been reported to alter the gut microbiome, cause damage to intestinal villi, and compromise the structural integrity of tight junctions [<xref rid="B40-genes-15-00975" ref-type="bibr">40</xref>], which can lead to gut leakiness. Indeed, HU can cause a transient release of lipopolysaccharide (LPS) in circulation and changes in the distribution of neutrophils and lymphocytes, [<xref rid="B41-genes-15-00975" ref-type="bibr">41</xref>] as well as an increase in circulating levels of the potent pro-inflammatory cytokine interferon &#947; (<italic toggle="yes">IFN&#947;</italic>) [<xref rid="B42-genes-15-00975" ref-type="bibr">42</xref>]. Further, synthetic bacterial DNA has been shown to induce a robust inflammatory response in the heart of mice [<xref rid="B43-genes-15-00975" ref-type="bibr">43</xref>]. Consistent with a potential role of gut permeability, we found upregulation of <italic toggle="yes">CD14</italic> in 14-day HU hearts. <italic toggle="yes">CD14</italic> is a surface receptor expressed in circulating monocytes/macrophages, which binds to LPS to induce an immune response [<xref rid="B44-genes-15-00975" ref-type="bibr">44</xref>]. Other key genes involved in the inflammatory response were also upregulated after 14 days of HU, including <italic toggle="yes">CD163</italic> and <italic toggle="yes">CD68</italic>. <italic toggle="yes">CD163</italic> is a marker for activated macrophages. <italic toggle="yes">CD163</italic>+ macrophages promote angiogenesis, vessel permeability, and leukocyte infiltration [<xref rid="B45-genes-15-00975" ref-type="bibr">45</xref>] and are increased in hearts of simian immunodeficiency virus-infected monkeys [<xref rid="B46-genes-15-00975" ref-type="bibr">46</xref>]. Further, <italic toggle="yes">CD68</italic> marks the monocyte/macrophage population. Both expression levels of <italic toggle="yes">CD68</italic> and immunopositive cell counts increase in the hearts of mice exposed to spaceflight-relevant doses (&lt;0.5 Gy) of radiation [<xref rid="B47-genes-15-00975" ref-type="bibr">47</xref>]. In addition, HU in mice increased hippocampal <italic toggle="yes">CD68</italic> levels, which mark activated microglial populations [<xref rid="B48-genes-15-00975" ref-type="bibr">48</xref>,<xref rid="B49-genes-15-00975" ref-type="bibr">49</xref>]. Collectively, the upregulation of <italic toggle="yes">CD14</italic>, <italic toggle="yes">CD68</italic>, and <italic toggle="yes">CD163</italic> expression would be consistent with macrophage infiltration in HU hearts. Humans in future deep space missions will experience extended periods of low-dose space radiation and microgravity. Hence, the impact of the predicted upregulation of macrophage activity on human cardiovascular health requires further study. <italic toggle="yes">Tlr8</italic> also was upregulated in the hearts of 14-day HU animals. Accumulating evidence demonstrates the important role of TLR signaling in the development of cardiovascular disease [<xref rid="B50-genes-15-00975" ref-type="bibr">50</xref>,<xref rid="B51-genes-15-00975" ref-type="bibr">51</xref>], whereas <italic toggle="yes">Tlr8</italic> transcripts increased in patients with enterovirus-induced dilated cardiomyopathy [<xref rid="B52-genes-15-00975" ref-type="bibr">52</xref>].</p><p>RNAseq results also suggest that HU in older males can perturb cardiac circadian clock signals. The circadian clock gene, <italic toggle="yes">Arntl (Bmal1)</italic>, was the fourth most downregulated gene in the HU group, while <italic toggle="yes">Per3</italic> was the most upregulated gene. Other circadian clock-related genes such as <italic toggle="yes">Per2</italic> and <italic toggle="yes">Clock</italic> were upregulated and downregulated, respectively. There is a growing appreciation for the role of clock genes in cardiovascular disease. Cardiac-specific deletion of <italic toggle="yes">Arntl</italic> leads to congestive heart failure during aging, upregulation of oxidative stress-responsive genes in hearts and altered energy metabolism [<xref rid="B53-genes-15-00975" ref-type="bibr">53</xref>]. In addition, <italic toggle="yes">Per2</italic> gene ablation worsens the inflammatory response to myocardial ischemia [<xref rid="B54-genes-15-00975" ref-type="bibr">54</xref>]. ISS crew experience circadian misalignment which leads to sleep&#8211;wake cycle disruption [<xref rid="B55-genes-15-00975" ref-type="bibr">55</xref>]. Bioinformatic analysis of tissues from rodent spaceflight and ground-based studies (e.g., skeletal muscle, adrenals, kidney, liver) consistently show that spaceflight and its analogs lead to altered expression of circadian clock-related genes including <italic toggle="yes">Per2</italic>, <italic toggle="yes">Arntl</italic>, and <italic toggle="yes">Clock</italic> [<xref rid="B56-genes-15-00975" ref-type="bibr">56</xref>]. Taken together, our findings and those of others show the importance of exploring the role of circadian clock signaling in spaceflight-induced tissue deficits.</p><p>RNAseq also revealed the enrichment of processes related to redox signaling, such as superoxide anion generation. Furthermore, 14 days of HU led to differential expression of a number of genes known to play a role in the defense against oxidative damage. In the current study, Clusterin <italic toggle="yes">(Clu),</italic> also known as Apolipoprotein J (<italic toggle="yes">ApoJ</italic>), was upregulated after 14 days of HU. Overexpression of <italic toggle="yes">Clu</italic> in rat ventricular cells has been reported to rescue angiotensin II-induced ROS production and apoptosis [<xref rid="B57-genes-15-00975" ref-type="bibr">57</xref>]. <italic toggle="yes">Ucp3</italic>, a member of the family of mitochondrial uncoupling proteins (UCPs), was downregulated at 14 days of HU. UCPs have a number of functions, such as dissipating the proton gradient in the mitochondria, which reduces ATP production, releasing energy as heat, and also play a role in the regulation of redox balance [<xref rid="B58-genes-15-00975" ref-type="bibr">58</xref>]. Compared to wild-type controls, the hearts of <italic toggle="yes">Ucp3</italic> knockout mice maintained in thermoneutral conditions have reduced mitochondrial complex activities as well as increased levels of ROS and oxidative stress markers [<xref rid="B59-genes-15-00975" ref-type="bibr">59</xref>]. Thus, the downregulation of <italic toggle="yes">Ucp3</italic> in the hearts of HU rats suggests that simulated microgravity alters redox signaling and energetic processes in the mitochondria, consistent with findings from spaceflight and analog studies of other tissues [<xref rid="B60-genes-15-00975" ref-type="bibr">60</xref>,<xref rid="B61-genes-15-00975" ref-type="bibr">61</xref>]. Regulator of Calcineurin 1 (<italic toggle="yes">Rcan1</italic>), which is downregulated in hearts after 14 days of HU, plays a role in NFAT/Calcineurin signaling and is implicated in CVD progression [<xref rid="B62-genes-15-00975" ref-type="bibr">62</xref>,<xref rid="B63-genes-15-00975" ref-type="bibr">63</xref>]. Deletion of <italic toggle="yes">Rcan1</italic> exacerbates the effects of septic cardiomyopathy and increases cardiac mitochondrial injury, as shown by elevated ROS levels and loss of mitochondrial membrane potential [<xref rid="B62-genes-15-00975" ref-type="bibr">62</xref>]. Taken together, our findings are in support of the hypothesis that simulated microgravity leads to altered redox signaling and function in the heart. In addition, these results are consistent with our earlier findings that hearts of mice that have been in space for 15 days show altered expression of genes regulating redox balance [<xref rid="B64-genes-15-00975" ref-type="bibr">64</xref>]. Taken together, the overall transcriptomic signature in the left ventricle of older males at 14 days of HU (~1 human year) suggests activation of the immune system and pro-inflammatory signaling, altered expression of circadian clock genes, and induction of signals that promote ROS production together with upregulation of select cellular defenses to oxidative damage. Therefore, our model predicts that in the absence of any mitigation strategies, extended spaceflight (&gt;a year) may upregulate pro-inflammatory signaling in cardiac tissue. Consistent with our hypothesis, simulated microgravity led to enhanced expression of genes involved in the inflammatory and oxidative stress responses. Therefore, mitigating excessive inflammation and ensuring optimum antioxidant defenses (e.g., via dietary supplementation) may be a useful approach to ensure long-term cardiac health in astronauts during deep space missions. The upregulation of complement activation genes in hearts of rodents exposed to HU needs further study to determine its underlying basis and long-term consequences for cardiac health. In addition, we have identified the molecular signature of cardiac tissue responses to HU. A subset of these differentially expressed genes could be tested as candidate circulating biomarkers for monitoring the trajectory of an astronaut&#8217;s response to spaceflight or predicting the need for medical intervention.</p></sec></body><back><ack><title>Acknowledgments</title><p>We are grateful to April Ronca and other members of Ames SC Division for coordinating this NASA-funded tissue-sharing opportunity. We also thank Sungshin Choi and other members of the NASA Ames and UC Davis dissection teams for assistance in collecting rat tissue samples.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-genes-15-00975"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/genes15080975/s1">https://www.mdpi.com/article/10.3390/genes15080975/s1</uri>, Table S1: List of groups and sample sizes included in analyses, Table S2: Results of functional enrichment analysis using Toppfun, Table S3: Results of human disease phenotype analysis using Toppfun, Table S4: Results of drug-gene association analysis using Toppfun.</p><supplementary-material id="genes-15-00975-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="genes-15-00975-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, Y.S., R.K.G. and C.G.T.T.; methodology, C.G.T.T., A. Sebastian, G.G.L., D.A.G., M.T., N.R.H., M.A. and M.C.; formal analysis, C.G.T.T., A. Sebastian, M.T., S.S., N.R.H., M.A. and M.C.; resources, R.K.G., G.G.L., D.A.G. and C.A.F.; visualization, C.G.T.T.; writing&#8212;original draft preparation, C.G.T.T.; writing&#8212;review and editing, all authors; project administration, T.M.H.-H.; supervision, C.G.T.T., R.K.G., A. Schreurs and T.M.H.-H.; funding acquisition, R.K.G., Y.S., A. Schreurs and C.A.F. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study protocol (Protocol 17390) was approved by the Institutional Animal Care and Use Committee of the University of California at Davis on 24 January 2013 and renewed annually for the duration of the project.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data are contained within the article or <xref rid="app1-genes-15-00975" ref-type="app">Supplementary Material</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-genes-15-00975"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norsk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Asmar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damgaard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>N.J.</given-names></name></person-group><article-title>Fluid shifts, vasodilatation and ambulatory blood pressure reduction during long duration spaceflight</article-title><source>J. Physiol.</source><year>2015</year><volume>593</volume><fpage>573</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2014.284869</pub-id><pub-id pub-id-type="pmid">25774397</pub-id><pub-id pub-id-type="pmcid">PMC4324706</pub-id></element-citation></ref><ref id="B2-genes-15-00975"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perhonen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Buckey</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Blomqvist</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Zerwekh</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Peshock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Weatherall</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B.D.</given-names></name></person-group><article-title>Cardiac atrophy after bed rest and spaceflight</article-title><source>J. Appl. Physiol.</source><year>2001</year><volume>91</volume><fpage>645</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1152/jappl.2001.91.2.645</pub-id><pub-id pub-id-type="pmid">11457776</pub-id></element-citation></ref><ref id="B3-genes-15-00975"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Summers</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Meck</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>T.G.</given-names></name></person-group><article-title>Mechanism of spaceflight-induced changes in left ventricular mass</article-title><source>Am. J. Cardiol.</source><year>2005</year><volume>95</volume><fpage>1128</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2005.01.033</pub-id><pub-id pub-id-type="pmid">15842991</pub-id></element-citation></ref><ref id="B4-genes-15-00975"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khine</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Steding-Ehrenborg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Kowal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Daniels</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Page</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Goldberger</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adams-Huet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bungo</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Effects of Prolonged Spaceflight on Atrial Size, Atrial Electrophysiology, and Risk of Atrial Fibrillation</article-title><source>Circ. Arrhythm. Electrophysiol.</source><year>2018</year><volume>11</volume><fpage>e005959</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.117.005959</pub-id><pub-id pub-id-type="pmid">29752376</pub-id></element-citation></ref><ref id="B5-genes-15-00975"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watenpaugh</surname><given-names>D.E.</given-names></name></person-group><article-title>Fluid volume control during short-term space flight and implications for human performance</article-title><source>J. Exp. Biol.</source><year>2001</year><volume>204</volume><fpage>3209</fpage><lpage>3215</lpage><pub-id pub-id-type="doi">10.1242/jeb.204.18.3209</pub-id><pub-id pub-id-type="pmid">11581336</pub-id></element-citation></ref><ref id="B6-genes-15-00975"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall-Goebel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Alferova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Arbeille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aunon-Chancellor</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.M.C.</given-names></name><name name-style="western"><surname>Macias</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Pattarini</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Assessment of Jugular Venous Blood Flow Stasis and Thrombosis During Spaceflight</article-title><source>JAMA Netw. Open</source><year>2019</year><volume>2</volume><fpage>e1915011</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.15011</pub-id><pub-id pub-id-type="pmid">31722025</pub-id><pub-id pub-id-type="pmcid">PMC6902784</pub-id></element-citation></ref><ref id="B7-genes-15-00975"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Migeotte</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Prisk</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>M.</given-names></name></person-group><article-title>Microgravity alters respiratory sinus arrhythmia and short-term heart rate variability in humans</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2003</year><volume>284</volume><fpage>H1995</fpage><lpage>H2006</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00409.2002</pub-id><pub-id pub-id-type="pmid">12560205</pub-id></element-citation></ref><ref id="B8-genes-15-00975"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.M.C.</given-names></name><name name-style="western"><surname>Feiveson</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stenger</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Platts</surname><given-names>S.H.</given-names></name></person-group><article-title>Orthostatic Intolerance After ISS and Space Shuttle Missions</article-title><source>Aerosp. Med. Hum. Perform.</source><year>2015</year><volume>86</volume><fpage>A54</fpage><lpage>A67</lpage><pub-id pub-id-type="doi">10.3357/AMHP.EC08.2015</pub-id><pub-id pub-id-type="pmid">26630196</pub-id></element-citation></ref><ref id="B9-genes-15-00975"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughson</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Arbeille</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shoemaker</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Rush</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Greaves</surname><given-names>D.K.</given-names></name></person-group><article-title>Increased postflight carotid artery stiffness and inflight insulin resistance resulting from 6-mo spaceflight in male and female astronauts</article-title><source>Am. J. Physiol. Heart Circ. Physiol.</source><year>2016</year><volume>310</volume><fpage>H628</fpage><lpage>H638</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00802.2015</pub-id><pub-id pub-id-type="pmid">26747504</pub-id></element-citation></ref><ref id="B10-genes-15-00975"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Globus</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Morey-Holton</surname><given-names>E.</given-names></name></person-group><article-title>Hindlimb unloading: Rodent analog for microgravity</article-title><source>J. Appl. Physiol.</source><year>2016</year><volume>120</volume><fpage>1196</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00997.2015</pub-id><pub-id pub-id-type="pmid">26869711</pub-id></element-citation></ref><ref id="B11-genes-15-00975"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morey-Holton</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Globus</surname><given-names>R.K.</given-names></name></person-group><article-title>Hindlimb unloading rodent model: Technical aspects</article-title><source>J. Appl. Physiol.</source><year>2002</year><volume>92</volume><fpage>1367</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00969.2001</pub-id><pub-id pub-id-type="pmid">11895999</pub-id></element-citation></ref><ref id="B12-genes-15-00975"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.B.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.Q.</given-names></name></person-group><article-title>Echocardiographic assessment of left ventricular structure and function after simulated weightlessness in rats</article-title><source>Space Med. Med. Eng. (Beijing)</source><year>1999</year><volume>12</volume><fpage>88</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12428650</pub-id></element-citation></ref><ref id="B13-genes-15-00975"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Pawelczyk</surname><given-names>J.A.</given-names></name></person-group><article-title>Cardiac atrophy after bed-rest deconditioning: A nonneural mechanism for orthostatic intolerance</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.96.2.517</pub-id><pub-id pub-id-type="pmid">9244220</pub-id></element-citation></ref><ref id="B14-genes-15-00975"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorfman</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Tillery</surname><given-names>T.</given-names></name><name name-style="western"><surname>Peshock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Macias</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Biolo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hargens</surname><given-names>A.R.</given-names></name></person-group><article-title>Cardiac atrophy in women following bed rest</article-title><source>J. Appl. Physiol.</source><year>2007</year><volume>103</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01162.2006</pub-id><pub-id pub-id-type="pmid">17379748</pub-id></element-citation></ref><ref id="B15-genes-15-00975"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westby</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Stenger</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Platts</surname><given-names>S.H.</given-names></name></person-group><article-title>Left ventricular remodeling during and after 60 days of sedentary head-down bed rest</article-title><source>J. Appl. Physiol.</source><year>2016</year><volume>120</volume><fpage>956</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00676.2015</pub-id><pub-id pub-id-type="pmid">26494448</pub-id><pub-id pub-id-type="pmcid">PMC4835908</pub-id></element-citation></ref><ref id="B16-genes-15-00975"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shibata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perhonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B.D.</given-names></name></person-group><article-title>Supine cycling plus volume loading prevent cardiovascular deconditioning during bed rest</article-title><source>J. Appl. Physiol.</source><year>2010</year><volume>108</volume><fpage>1177</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01408.2009</pub-id><pub-id pub-id-type="pmid">20223994</pub-id><pub-id pub-id-type="pmcid">PMC3774511</pub-id></element-citation></ref><ref id="B17-genes-15-00975"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsvirkun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bourreau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mieuset</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vinogradova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Larina</surname><given-names>I.</given-names></name><name name-style="western"><surname>Navasiolava</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gauquelin-Koch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gharib</surname><given-names>C.</given-names></name><name name-style="western"><surname>Custaud</surname><given-names>M.A.</given-names></name></person-group><article-title>Contribution of social isolation, restraint, and hindlimb unloading to changes in hemodynamic parameters and motion activity in rats</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e39923</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0039923</pub-id><pub-id pub-id-type="pmid">22768322</pub-id><pub-id pub-id-type="pmcid">PMC3388052</pub-id></element-citation></ref><ref id="B18-genes-15-00975"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Respress</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gershovich</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Skapura</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Wehrens</surname><given-names>X.H.</given-names></name></person-group><article-title>Long-term simulated microgravity causes cardiac RyR2 phosphorylation and arrhythmias in mice</article-title><source>Int. J. Cardiol.</source><year>2014</year><volume>176</volume><fpage>994</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2014.08.138</pub-id><pub-id pub-id-type="pmid">25227892</pub-id><pub-id pub-id-type="pmcid">PMC4195800</pub-id></element-citation></ref><ref id="B19-genes-15-00975"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soulsby</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J.L.</given-names></name></person-group><article-title>Effects of aminoguanidine on tissue oxidative stress induced by hindlimb unloading in rats</article-title><source>Ann. Clin. Lab. Sci.</source><year>2009</year><volume>39</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">19201744</pub-id></element-citation></ref><ref id="B20-genes-15-00975"><label>20.</label><element-citation publication-type="webpage"><article-title>Morpheus</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://software.broadinstitute.org/morpheus/" ext-link-type="uri">https://software.broadinstitute.org/morpheus/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-04-13">(accessed on 13 April 2019)</date-in-citation></element-citation></ref><ref id="B21-genes-15-00975"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aronow</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Jegga</surname><given-names>A.G.</given-names></name></person-group><article-title>Disease candidate gene identification and prioritization using protein interaction networks</article-title><source>BMC Bioinform.</source><year>2009</year><volume>10</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-73</pub-id><pub-id pub-id-type="pmcid">PMC2657789</pub-id><pub-id pub-id-type="pmid">19245720</pub-id></element-citation></ref><ref id="B22-genes-15-00975"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bardes</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Aronow</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Jegga</surname><given-names>A.G.</given-names></name></person-group><article-title>ToppGene Suite for gene list enrichment analysis and candidate gene prioritization</article-title><source>Nucleic Acids Res.</source><year>2009</year><volume>37</volume><fpage>W305</fpage><lpage>W311</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp427</pub-id><pub-id pub-id-type="pmid">19465376</pub-id><pub-id pub-id-type="pmcid">PMC2703978</pub-id></element-citation></ref><ref id="B23-genes-15-00975"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulanova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gritsyna</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Salmov</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lomonosova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Belova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nemirovskaya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shenkman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vikhlyantsev</surname><given-names>I.</given-names></name></person-group><article-title>Effect of L-Arginine on Titin Expression in Rat Soleus Muscle After Hindlimb Unloading</article-title><source>Front. Physiol.</source><year>2019</year><volume>10</volume><elocation-id>1221</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.01221</pub-id><pub-id pub-id-type="pmid">31616317</pub-id><pub-id pub-id-type="pmcid">PMC6764413</pub-id></element-citation></ref><ref id="B24-genes-15-00975"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marzuca-Nassr</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Fortes</surname><given-names>M.A.S.</given-names></name><name name-style="western"><surname>Guimaraes-Ferreira</surname><given-names>L.</given-names></name><name name-style="western"><surname>Murata</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Vitzel</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Vasconcelos</surname><given-names>D.A.A.</given-names></name><name name-style="western"><surname>Bassit</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Curi</surname><given-names>R.</given-names></name></person-group><article-title>Short-term creatine supplementation changes protein metabolism signaling in hindlimb suspension</article-title><source>Braz. J. Med. Biol. Res.</source><year>2019</year><volume>52</volume><elocation-id>e8391</elocation-id><pub-id pub-id-type="doi">10.1590/1414-431x20198391</pub-id><pub-id pub-id-type="pmid">31596311</pub-id><pub-id pub-id-type="pmcid">PMC6787955</pub-id></element-citation></ref><ref id="B25-genes-15-00975"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dehority</surname><given-names>W.</given-names></name><name name-style="western"><surname>Halloran</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Bikle</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Curren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kostenuik</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wronski</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rabkin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bouraoui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Morey-Holton</surname><given-names>E.</given-names></name></person-group><article-title>Bone and hormonal changes induced by skeletal unloading in the mature male rat</article-title><source>Am. J. Physiol.</source><year>1999</year><volume>276</volume><fpage>E62</fpage><lpage>E69</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.1999.276.1.E62</pub-id><pub-id pub-id-type="pmid">9886951</pub-id></element-citation></ref><ref id="B26-genes-15-00975"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>North</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jeganathan</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Michan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Sauve</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>SIRT2 induces the checkpoint kinase BubR1 to increase lifespan</article-title><source>EMBO J.</source><year>2014</year><volume>33</volume><fpage>1438</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.15252/embj.201386907</pub-id><pub-id pub-id-type="pmid">24825348</pub-id><pub-id pub-id-type="pmcid">PMC4194088</pub-id></element-citation></ref><ref id="B27-genes-15-00975"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Q.</given-names></name></person-group><article-title>SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction</article-title><source>Aging Cell</source><year>2007</year><volume>6</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1111/j.1474-9726.2007.00304.x</pub-id><pub-id pub-id-type="pmid">17521387</pub-id></element-citation></ref><ref id="B28-genes-15-00975"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seawright</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Samman</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Melnyk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koturbash</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hauer-Jensen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Effects of low-dose rate gamma-irradiation combined with simulated microgravity on markers of oxidative stress, DNA methylation potential, and remodeling in the mouse heart</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0180594</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0180594</pub-id><pub-id pub-id-type="pmid">28678877</pub-id><pub-id pub-id-type="pmcid">PMC5498037</pub-id></element-citation></ref><ref id="B29-genes-15-00975"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricklin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lambris</surname><given-names>J.D.</given-names></name></person-group><article-title>Complement in immune and inflammatory disorders: Pathophysiological mechanisms</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>3831</fpage><lpage>3838</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1203487</pub-id><pub-id pub-id-type="pmid">23564577</pub-id><pub-id pub-id-type="pmcid">PMC3623009</pub-id></element-citation></ref><ref id="B30-genes-15-00975"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjerre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Flyvbjerg</surname><given-names>A.</given-names></name></person-group><article-title>Complement activation and cardiovascular disease</article-title><source>Horm. Metab. Res.</source><year>2008</year><volume>40</volume><fpage>626</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1055/s-0028-1083786</pub-id><pub-id pub-id-type="pmid">18792874</pub-id></element-citation></ref><ref id="B31-genes-15-00975"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlov</surname><given-names>V.I.</given-names></name><name name-style="western"><surname>Skjoedt</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Siow Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rosbjerg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garred</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>G.L.</given-names></name></person-group><article-title>Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis</article-title><source>Circulation</source><year>2012</year><volume>126</volume><fpage>2227</fpage><lpage>2235</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.123968</pub-id><pub-id pub-id-type="pmid">23032324</pub-id><pub-id pub-id-type="pmcid">PMC3500764</pub-id></element-citation></ref><ref id="B32-genes-15-00975"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kinser</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paulling</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gilkeson</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>S.</given-names></name></person-group><article-title>The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice</article-title><source>Arthritis Rheum.</source><year>2011</year><volume>63</volume><fpage>1076</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1002/art.30222</pub-id><pub-id pub-id-type="pmid">21452327</pub-id><pub-id pub-id-type="pmcid">PMC3079315</pub-id></element-citation></ref><ref id="B33-genes-15-00975"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name></person-group><article-title>Increased complements and high-sensitivity C-reactive protein predict heart failure in acute myocardial infarction</article-title><source>Biomed. Rep.</source><year>2016</year><volume>5</volume><fpage>761</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.3892/br.2016.793</pub-id><pub-id pub-id-type="pmid">28105343</pub-id><pub-id pub-id-type="pmcid">PMC5228438</pub-id></element-citation></ref><ref id="B34-genes-15-00975"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>D.</given-names></name></person-group><article-title>Complement components sC5b-9 and CH50 predict prognosis in heart failure patients combined with hypertension</article-title><source>Am. J. Hypertens.</source><year>2019</year><volume>33</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1093/ajh/hpz140</pub-id><pub-id pub-id-type="pmid">31429866</pub-id></element-citation></ref><ref id="B35-genes-15-00975"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>K.A.L.</given-names></name><name name-style="western"><surname>Patzelt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sauter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gekeler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klingel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kandolf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seizer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gawaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geisler</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Myocardial expression of the anaphylatoxin receptor C3aR is associated with cardiac inflammation and prognosis in patients with non-ischaemic heart failure</article-title><source>ESC Heart Fail.</source><year>2018</year><volume>5</volume><fpage>846</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1002/ehf2.12298</pub-id><pub-id pub-id-type="pmid">30168657</pub-id><pub-id pub-id-type="pmcid">PMC6165948</pub-id></element-citation></ref><ref id="B36-genes-15-00975"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Hoog</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Timmers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Duijvenvoorde</surname><given-names>A.</given-names></name><name name-style="western"><surname>De Jager</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Van Middelaar</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Smeets</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Woodruff</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Doevendans</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pasterkamp</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hack</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury</article-title><source>Cardiovasc. Res.</source><year>2014</year><volume>103</volume><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvu153</pub-id><pub-id pub-id-type="pmid">24935433</pub-id></element-citation></ref><ref id="B37-genes-15-00975"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>C.</given-names></name><name name-style="western"><surname>Larmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hilfiker-Kleiner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Theilmeier</surname><given-names>G.</given-names></name></person-group><article-title>The receptor for activated complement factor 5 (C5aR) conveys myocardial ischemic damage by mediating neutrophil transmigration</article-title><source>Immunobiology</source><year>2013</year><volume>218</volume><fpage>1131</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2013.03.006</pub-id><pub-id pub-id-type="pmid">23642836</pub-id></element-citation></ref><ref id="B38-genes-15-00975"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenei</surname><given-names>Z.M.</given-names></name><name name-style="western"><surname>Zima</surname><given-names>E.</given-names></name><name name-style="western"><surname>Csuka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Munthe-Fog</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Szeplaki</surname><given-names>G.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>D.</given-names></name><name name-style="western"><surname>Karadi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prohaszka</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Garred</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Complement activation and its prognostic role in post-cardiac arrest patients</article-title><source>Scand. J. Immunol.</source><year>2014</year><volume>79</volume><fpage>404</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1111/sji.12167</pub-id><pub-id pub-id-type="pmid">24612379</pub-id></element-citation></ref><ref id="B39-genes-15-00975"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashirina</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Percy</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Pastushkova</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Borchers</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Kireev</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ivanisenko</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Kononikhin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Nikolaev</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Larina</surname><given-names>I.M.</given-names></name></person-group><article-title>The molecular mechanisms driving physiological changes after long duration space flights revealed by quantitative analysis of human blood proteins</article-title><source>BMC Med. Genom.</source><year>2019</year><volume>12</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-019-0490-y</pub-id><pub-id pub-id-type="pmid">30871558</pub-id><pub-id pub-id-type="pmcid">PMC6416832</pub-id></element-citation></ref><ref id="B40-genes-15-00975"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Simulated microgravity disrupts intestinal homeostasis and increases colitis susceptibility</article-title><source>FASEB J.</source><year>2015</year><volume>29</volume><fpage>3263</fpage><lpage>3273</lpage><pub-id pub-id-type="doi">10.1096/fj.15-271700</pub-id><pub-id pub-id-type="pmid">25877215</pub-id></element-citation></ref><ref id="B41-genes-15-00975"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanzari</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Diffenderfer</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kennedy</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>Effect of solar particle event radiation and hindlimb suspension on gastrointestinal tract bacterial translocation and immune activation</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e44329</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044329</pub-id><pub-id pub-id-type="pmid">23028522</pub-id><pub-id pub-id-type="pmcid">PMC3446907</pub-id></element-citation></ref><ref id="B42-genes-15-00975"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Responses of Intestinal Mucosal Barrier Functions of Rats to Simulated Weightlessness</article-title><source>Front. Physiol.</source><year>2018</year><volume>9</volume><elocation-id>729</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00729</pub-id><pub-id pub-id-type="pmid">29962963</pub-id><pub-id pub-id-type="pmcid">PMC6011188</pub-id></element-citation></ref><ref id="B43-genes-15-00975"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knuefermann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwederski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Velten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krings</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ehrentraut</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rudiger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dreiner</surname><given-names>U.</given-names></name><name name-style="western"><surname>Grohe</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: Role of toll-like receptor 9</article-title><source>Cardiovasc. Res.</source><year>2008</year><volume>78</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvn011</pub-id><pub-id pub-id-type="pmid">18194990</pub-id></element-citation></ref><ref id="B44-genes-15-00975"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Tobias</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Ulevitch</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Mathison</surname><given-names>J.C.</given-names></name></person-group><article-title>CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein</article-title><source>Science</source><year>1990</year><volume>249</volume><fpage>1431</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1126/science.1698311</pub-id><pub-id pub-id-type="pmid">1698311</pub-id></element-citation></ref><ref id="B45-genes-15-00975"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Akahori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harari</surname><given-names>E.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Polavarapu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karmali</surname><given-names>V.</given-names></name><name name-style="western"><surname>Otsuka</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gannon</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Braumann</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Dickinson</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>1106</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1172/JCI93025</pub-id><pub-id pub-id-type="pmid">29457790</pub-id><pub-id pub-id-type="pmcid">PMC5824873</pub-id></element-citation></ref><ref id="B46-genes-15-00975"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sulciner</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Nowicki</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Burdo</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K.C.</given-names></name></person-group><article-title>Elevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis</article-title><source>AIDS Res. Hum. Retroviruses</source><year>2014</year><volume>30</volume><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1089/aid.2013.0268</pub-id><pub-id pub-id-type="pmid">24524407</pub-id><pub-id pub-id-type="pmcid">PMC4076976</pub-id></element-citation></ref><ref id="B47-genes-15-00975"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seawright</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Sridharan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Landes</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koturbash</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Miousse</surname><given-names>I.R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>G.A.</given-names></name><etal/></person-group><article-title>Effects of low-dose oxygen ions and protons on cardiac function and structure in male C57BL/6J mice</article-title><source>Life Sci. Space Res.</source><year>2019</year><volume>20</volume><fpage>72</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.lssr.2019.01.003</pub-id><pub-id pub-id-type="pmid">30797436</pub-id><pub-id pub-id-type="pmcid">PMC6391741</pub-id></element-citation></ref><ref id="B48-genes-15-00975"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rubinstein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kiffer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Puukila</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Goo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luthens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schreurs</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Steczina</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tahimic</surname><given-names>C.G.T.</given-names></name><etal/></person-group><article-title>Mitochondria-Targeted Human Catalase in the Mouse Longevity MCAT Model Mitigates Head-Tilt Bedrest-Induced Neuro-Inflammation in the Hippocampus</article-title><source>Life</source><year>2022</year><volume>12</volume><elocation-id>1838</elocation-id><pub-id pub-id-type="doi">10.3390/life12111838</pub-id><pub-id pub-id-type="pmid">36362993</pub-id><pub-id pub-id-type="pmcid">PMC9695374</pub-id></element-citation></ref><ref id="B49-genes-15-00975"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Harandi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>O.</given-names></name><name name-style="western"><surname>Irby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cornejal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sattler</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Influence of the spaceflight environment on macrophage lineages</article-title><source>NPJ Microgravity</source><year>2024</year><volume>10</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1038/s41526-023-00293-0</pub-id><pub-id pub-id-type="pmid">38862517</pub-id><pub-id pub-id-type="pmcid">PMC11166655</pub-id></element-citation></ref><ref id="B50-genes-15-00975"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name></person-group><article-title>The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure</article-title><source>Mediators Inflamm.</source><year>2018</year><volume>2018</volume><fpage>9874109</fpage><pub-id pub-id-type="doi">10.1155/2018/9874109</pub-id><pub-id pub-id-type="pmid">29576748</pub-id><pub-id pub-id-type="pmcid">PMC5822798</pub-id></element-citation></ref><ref id="B51-genes-15-00975"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parizadeh</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ghandehari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heydari-Majd</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seifi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mardani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parizadeh</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ghayour-Mobarhan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferns</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hassanian</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Avan</surname><given-names>A.</given-names></name></person-group><article-title>Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease</article-title><source>Curr. Pharm. Des.</source><year>2018</year><volume>24</volume><fpage>1887</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.2174/1381612824666180614090224</pub-id><pub-id pub-id-type="pmid">29898648</pub-id></element-citation></ref><ref id="B52-genes-15-00975"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satoh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akatsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Minami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name></person-group><article-title>Association between toll-like receptor 8 expression and adverse clinical outcomes in patients with enterovirus-associated dilated cardiomyopathy</article-title><source>Am. Heart J.</source><year>2007</year><volume>154</volume><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2007.05.010</pub-id><pub-id pub-id-type="pmid">17719310</pub-id></element-citation></ref><ref id="B53-genes-15-00975"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohsaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Das</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Deguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gouraud</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Waki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muragaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>M.</given-names></name></person-group><article-title>The circadian clock maintains cardiac function by regulating mitochondrial metabolism in mice</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e112811</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0112811</pub-id><pub-id pub-id-type="pmid">25389966</pub-id><pub-id pub-id-type="pmcid">PMC4229239</pub-id></element-citation></ref><ref id="B54-genes-15-00975"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonney</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kominsky</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brodsky</surname><given-names>K.</given-names></name><name name-style="western"><surname>Eltzschig</surname><given-names>H.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eckle</surname><given-names>T.</given-names></name></person-group><article-title>Cardiac Per2 functions as novel link between fatty acid metabolism and myocardial inflammation during ischemia and reperfusion injury of the heart</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e71493</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0071493</pub-id><pub-id pub-id-type="pmid">23977055</pub-id><pub-id pub-id-type="pmcid">PMC3748049</pub-id></element-citation></ref><ref id="B55-genes-15-00975"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn-Evans</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Barger</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Kubey</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Czeisler</surname><given-names>C.A.</given-names></name></person-group><article-title>Circadian misalignment affects sleep and medication use before and during spaceflight</article-title><source>NPJ Microgravity</source><year>2016</year><volume>2</volume><fpage>15019</fpage><pub-id pub-id-type="doi">10.1038/npjmgrav.2015.19</pub-id><pub-id pub-id-type="pmid">28725719</pub-id><pub-id pub-id-type="pmcid">PMC5515517</pub-id></element-citation></ref><ref id="B56-genes-15-00975"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Rutter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Muratani</surname><given-names>M.</given-names></name></person-group><article-title>Integrated RNA-seq Analysis Indicates Asynchrony in Clock Genes between Tissues under Spaceflight</article-title><source>Life</source><year>2020</year><volume>10</volume><elocation-id>196</elocation-id><pub-id pub-id-type="doi">10.3390/life10090196</pub-id><pub-id pub-id-type="pmid">32933026</pub-id><pub-id pub-id-type="pmcid">PMC7555136</pub-id></element-citation></ref><ref id="B57-genes-15-00975"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ru</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name></person-group><article-title>Apolipoprotein-J prevents angiotensin II-induced apoptosis in neonatal rat ventricular cells</article-title><source>Lipids Health Dis.</source><year>2015</year><volume>14</volume><fpage>114</fpage><pub-id pub-id-type="doi">10.1186/s12944-015-0118-y</pub-id><pub-id pub-id-type="pmid">26391229</pub-id><pub-id pub-id-type="pmcid">PMC4578334</pub-id></element-citation></ref><ref id="B58-genes-15-00975"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirschenson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Melgar-Bermudez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mailloux</surname><given-names>R.J.</given-names></name></person-group><article-title>The Uncoupling Proteins: A Systematic Review on the Mechanism Used in the Prevention of Oxidative Stress</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>322</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11020322</pub-id><pub-id pub-id-type="pmid">35204205</pub-id><pub-id pub-id-type="pmcid">PMC8868465</pub-id></element-citation></ref><ref id="B59-genes-15-00975"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Napolitano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fasciolo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Magnacca</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goglia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lombardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Venditti</surname><given-names>P.</given-names></name></person-group><article-title>Oxidative damage and mitochondrial functionality in hearts from KO UCP3 mice housed at thermoneutrality</article-title><source>J. Physiol. Biochem.</source><year>2022</year><volume>78</volume><fpage>415</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1007/s13105-022-00882-9</pub-id><pub-id pub-id-type="pmid">35237934</pub-id></element-citation></ref><ref id="B60-genes-15-00975"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silveira</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Fazelinia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Laiakis</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Meydan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kidane</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rathi</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Stear</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Comprehensive Multi-omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact</article-title><source>Cell</source><year>2020</year><volume>183</volume><fpage>1185</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.002</pub-id><pub-id pub-id-type="pmid">33242417</pub-id><pub-id pub-id-type="pmcid">PMC7870178</pub-id></element-citation></ref><ref id="B61-genes-15-00975"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indo</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Majima</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suenaga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>S.</given-names></name><name name-style="western"><surname>Higashibata</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ishioka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kanekura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nonaka</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Changes in mitochondrial homeostasis and redox status in astronauts following long stays in space</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>39015</fpage><pub-id pub-id-type="doi">10.1038/srep39015</pub-id><pub-id pub-id-type="pmid">27982062</pub-id><pub-id pub-id-type="pmcid">PMC5159838</pub-id></element-citation></ref><ref id="B62-genes-15-00975"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>RCAN1 deficiency aggravates sepsis-induced cardiac remodeling and dysfunction by accelerating mitochondrial pathological fission</article-title><source>Inflamm. Res.</source><year>2022</year><volume>71</volume><fpage>1589</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1007/s00011-022-01628-5</pub-id><pub-id pub-id-type="pmid">36305917</pub-id></element-citation></ref><ref id="B63-genes-15-00975"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>RCAN1 in cardiovascular diseases: Molecular mechanisms and a potential therapeutic target</article-title><source>Mol. Med.</source><year>2020</year><volume>26</volume><fpage>118</fpage><pub-id pub-id-type="doi">10.1186/s10020-020-00249-0</pub-id><pub-id pub-id-type="pmid">33267791</pub-id><pub-id pub-id-type="pmcid">PMC7709393</pub-id></element-citation></ref><ref id="B64-genes-15-00975"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tahimic</surname><given-names>C.G.T.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>E.A.C.</given-names></name><name name-style="western"><surname>Globus</surname><given-names>R.K.</given-names></name></person-group><article-title>Spaceflight Modulates the Expression of Key Oxidative Stress and Cell Cycle Related Genes in Heart</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>9088</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22169088</pub-id><pub-id pub-id-type="pmid">34445793</pub-id><pub-id pub-id-type="pmcid">PMC8396460</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="genes-15-00975-f001" orientation="portrait"><label>Figure 1</label><caption><p>Body weights of animals included in this study. NL: normally loaded; HU: hindlimb unloading; Rel: reambulated (reloading). The HU group was compared to their age- and sex-matched NL controls by Student&#8217;s <italic toggle="yes">t</italic>-test. Sample sizes: N = 5&#8211;8/group for all groups except for 90D older males, where N = 3. Values depicted are means and standard deviation. * Significant at <italic toggle="yes">p</italic> &lt; 0.05 by Student&#8217;s <italic toggle="yes">t</italic>-test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g001.jpg"/></fig><fig position="float" id="genes-15-00975-f002" orientation="portrait"><label>Figure 2</label><caption><p>8-hydroxydeoxyguanosine (8-OHdG) levels in left ventricular tissue as measured by ELISA. NL: normally loaded control, HU: hindlimb unloading, 7D Rel: 90D HU + 7D reloading and normally loaded control (NL). The HU groups were compared to their age- and sex-matched NL controls by Student&#8217;s <italic toggle="yes">t</italic>-test. Sample sizes: N = 5&#8211;8/group for all groups except for 90D older males, where N = 3. Values depicted are means and standard deviation. * Significant at <italic toggle="yes">p</italic> &lt; 0.05 by Student&#8217;s <italic toggle="yes">t</italic>-test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g002.jpg"/></fig><fig position="float" id="genes-15-00975-f003" orientation="portrait"><label>Figure 3</label><caption><p>Transcript levels of (<bold>A</bold>) <italic toggle="yes">Nfe2l2</italic>, (<bold>B</bold>) <italic toggle="yes">Sod1</italic>, (<bold>C</bold>) <italic toggle="yes">Sod2</italic>, and (<bold>D</bold>) <italic toggle="yes">Sirt1</italic> in left ventricular wall as measured by qPCR. Values depicted are mean fold changes relative to young male control at 14 days of treatment as determined by the &#916;&#916;Ct method. Errors bars show upper and lower ranges. NL: normally loaded control, HU: hindlimb unloading, 90D Rel: 90D HU + 90D reloading and NL control. Sample sizes: N = 3&#8211;7/group. * Significant at <italic toggle="yes">p</italic> &lt; 0.05 by Student&#8217;s <italic toggle="yes">t</italic>-test by comparing HU with age- and sex-matched NL control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g003.jpg"/></fig><fig position="float" id="genes-15-00975-f004" orientation="portrait"><label>Figure 4</label><caption><p>PCA plot of transcriptomic data from older males that underwent 14 days of HU (gray triangles) and corresponding NL controls (black circles). Animal ID is indicated by the letter &#8220;R&#8221; succeeded by numbers.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g004.jpg"/></fig><fig position="float" id="genes-15-00975-f005" orientation="portrait"><label>Figure 5</label><caption><p>Heatmap showing normalized counts of differentially expressed genes from older male 14D NL and HU groups. Each cell corresponds to a gene. Red: Upregulated in 14D HU relative to NL group. Blue: Downregulated in 14D HU relative to NL group. Magnitude of upregulation or downregulation is proportional to the intensity of red or blue. Deepest red: most upregulated; deepest blue: most downregulated.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g005.jpg"/></fig><fig position="float" id="genes-15-00975-f006" orientation="portrait"><label>Figure 6</label><caption><p>Top 10 upregulated and downregulated genes in older male 14D HU relative to NL groups. Log2 FC: Log2 fold change. Refer to <xref rid="genes-15-00975-t001" ref-type="table">Table 1</xref> for full list of DEGs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g006.jpg"/></fig><fig position="float" id="genes-15-00975-f007" orientation="portrait"><label>Figure 7</label><caption><p>Select enriched gene ontology (GO) terms for biological processes in older male 14D HU group relative to NL group. Gene count refers to the number of DEGs that matched the GO term. The vertical bar represents the color scale of the FDR with black representing the lowest FDR. Refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S2</xref> for the full list of GO terms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="genes-15-00975-g007.jpg"/></fig><table-wrap position="float" id="genes-15-00975-t001" orientation="portrait"><object-id pub-id-type="pii">genes-15-00975-t001_Table 1</object-id><label>Table 1</label><caption><p>Differentially expressed genes (DEGs) in older male 14D HU group relative to age- and sex- matched NL control group. DEGs were selected using an adj <italic toggle="yes">p</italic>-value &lt; 0.05 at a log2 fold change cut-off &gt; 0.3 or &lt;&#8722;0.3. Total DEGs: 125 (48 upregulated and 77 downregulated).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DEGs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Log2 FC</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic> adj</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Name</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Actg2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0241</td><td align="center" valign="middle" rowspan="1" colspan="1">Actin, &#947; 2, smooth muscle, enteric</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Adhfe1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.53</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td><td align="center" valign="middle" rowspan="1" colspan="1">Alcohol dehydrogenase, iron-containing, 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Alox5ap</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0454</td><td align="center" valign="middle" rowspan="1" colspan="1">Arachidonate 5-lipoxygenase activating protein</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Aplnr</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0457</td><td align="center" valign="middle" rowspan="1" colspan="1">Apelin receptor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Aqp7</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">Aquaporin 7</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Arl11</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0357</td><td align="center" valign="middle" rowspan="1" colspan="1">ADP-ribosylation factor-like GTPase 11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Arntl</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.92</td><td align="center" valign="middle" rowspan="1" colspan="1">1.77 &#215; 10<sup>&#8722;12</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Aryl hydrocarbon receptor nuclear translocator-like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Asb2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">Ankyrin repeat and SOCS box-containing 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Atp2a1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0284</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Atp4a</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0075</td><td align="center" valign="middle" rowspan="1" colspan="1">ATPase H+/K+ transporting subunit &#945;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bcat2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0038</td><td align="center" valign="middle" rowspan="1" colspan="1">Branched chain amino acid transaminase 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bckdha</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0083</td><td align="center" valign="middle" rowspan="1" colspan="1">Branched chain ketoacid dehydrogenase E1, &#945; polypeptide</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bcl6b</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0055</td><td align="center" valign="middle" rowspan="1" colspan="1">BCL6B, transcription repressor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">C1qa</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0483</td><td align="center" valign="middle" rowspan="1" colspan="1">Complement C1q A chain</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">C1qb</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005</td><td align="center" valign="middle" rowspan="1" colspan="1">Complement C1q B chain</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">C1qc</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">Complement C1q C chain</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">C5ar1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0483</td><td align="center" valign="middle" rowspan="1" colspan="1">Complement C5a receptor 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Car4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0017</td><td align="center" valign="middle" rowspan="1" colspan="1">Carbonic anhydrase 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cd14</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0314</td><td align="center" valign="middle" rowspan="1" colspan="1">CD14 molecule</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cd163</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">CD163 molecule</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cd44</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0353</td><td align="center" valign="middle" rowspan="1" colspan="1">CD44 molecule</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cd68</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0059</td><td align="center" valign="middle" rowspan="1" colspan="1">CD68 molecule</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cd93</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0065</td><td align="center" valign="middle" rowspan="1" colspan="1">CD93 molecule</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cdkn1a</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0011</td><td align="center" valign="middle" rowspan="1" colspan="1">Cyclin-dependent kinase inhibitor 1A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Cited4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.52</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0296</td><td align="center" valign="middle" rowspan="1" colspan="1">Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Clec4a1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0121</td><td align="center" valign="middle" rowspan="1" colspan="1">C-type lectin domain family 4, member A1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Clock</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">Clock circadian regulator</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Clu</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0055</td><td align="center" valign="middle" rowspan="1" colspan="1">Clusterin</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Col5a3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0280</td><td align="center" valign="middle" rowspan="1" colspan="1">Collagen type V &#945; 3 chain</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Crispld2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.45</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0234</td><td align="center" valign="middle" rowspan="1" colspan="1">Cysteine-rich secretory protein LCCL domain-containing 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Csf1r</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0111</td><td align="center" valign="middle" rowspan="1" colspan="1">Colony stimulating factor 1 receptor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Dkk3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0351</td><td align="center" valign="middle" rowspan="1" colspan="1">Dickkopf WNT signaling pathway inhibitor 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Dot1l</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0190</td><td align="center" valign="middle" rowspan="1" colspan="1">DOT1-like histone lysine methyltransferase</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ecrg4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.27</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0299</td><td align="center" valign="middle" rowspan="1" colspan="1">ECRG4 augurin precursor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Eepd1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">Endonuclease/exonuclease/phosphatase family domain-containing 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ephx1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">Epoxide hydrolase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Exoc4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0073</td><td align="center" valign="middle" rowspan="1" colspan="1">Exocyst complex component 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">F5</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0345</td><td align="center" valign="middle" rowspan="1" colspan="1">Coagulation factor V</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fabp3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03 &#215; 10<sup>&#8722;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Fatty acid-binding protein 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fam160a1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0369</td><td align="center" valign="middle" rowspan="1" colspan="1">Family with sequence similarity 160, member A1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fam220a</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0010</td><td align="center" valign="middle" rowspan="1" colspan="1">Family with sequence similarity 220, member A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fam26e</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0235</td><td align="center" valign="middle" rowspan="1" colspan="1">Calcium homeostasis modulator family member 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fcgr2b</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0314</td><td align="center" valign="middle" rowspan="1" colspan="1">Fc fragment of IgG receptor IIb</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fcna</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td><td align="center" valign="middle" rowspan="1" colspan="1">Ficolin A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Fhl2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0121</td><td align="center" valign="middle" rowspan="1" colspan="1">Four and a half LIM domains 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Gnb3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0093</td><td align="center" valign="middle" rowspan="1" colspan="1">G protein subunit &#946; 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Gng2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0457</td><td align="center" valign="middle" rowspan="1" colspan="1">G protein subunit &#947; 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Gpsm1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0063</td><td align="center" valign="middle" rowspan="1" colspan="1">G-protein signaling modulator 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Grip2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0022</td><td align="center" valign="middle" rowspan="1" colspan="1">Glutamate receptor interacting protein 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Gsn</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.49</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="middle" rowspan="1" colspan="1">Gelsolin</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Gstz1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.69</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0006</td><td align="center" valign="middle" rowspan="1" colspan="1">Glutathione S-transferase zeta 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Hadh</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.37</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 &#215; 10<sup>&#8722;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Hydroxyacyl-CoA dehydrogenase</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Heyl</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0105</td><td align="center" valign="middle" rowspan="1" colspan="1">Hairy/enhancer-of-split related with YRPW motif-like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Hspa5</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0456</td><td align="center" valign="middle" rowspan="1" colspan="1">Heat shock protein family A member 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Inha</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0345</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibin subunit &#945;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ispd</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.44</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0190</td><td align="center" valign="middle" rowspan="1" colspan="1">Isoprenoid synthase domain-containing</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Itga6</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.36</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0011</td><td align="center" valign="middle" rowspan="1" colspan="1">Integrin subunit &#945; 6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Itgam</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.90</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0061</td><td align="center" valign="middle" rowspan="1" colspan="1">Integrin subunit &#945; M</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Itgb2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0108</td><td align="center" valign="middle" rowspan="1" colspan="1">Integrin subunit &#946; 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Kank1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.39</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0307</td><td align="center" valign="middle" rowspan="1" colspan="1">KN motif and ankyrin repeat domains 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Kcnma1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2.16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="middle" rowspan="1" colspan="1">Potassium large conductance calcium-activated channel, subfamily M, &#945; member 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Laptm5</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0117</td><td align="center" valign="middle" rowspan="1" colspan="1">Lysosomal protein transmembrane 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Lbh</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0226</td><td align="center" valign="middle" rowspan="1" colspan="1">Limb bud and heart development</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Lcp1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0162</td><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocyte cytosolic protein 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Leo1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0295</td><td align="center" valign="middle" rowspan="1" colspan="1">LEO1 homolog, Paf1/RNA polymerase II complex component</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Lgals3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0077</td><td align="center" valign="middle" rowspan="1" colspan="1">Galectin 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Lilrb3l</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0435</td><td align="center" valign="middle" rowspan="1" colspan="1">Leukocyte immunoglobulin-like receptor subfamily B member 3-like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Limd1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.48</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td><td align="center" valign="middle" rowspan="1" colspan="1">LIM domain-containing 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Lingo4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.55</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0142</td><td align="center" valign="middle" rowspan="1" colspan="1">Leucine-rich repeat and Ig domain-containing 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Map3k7cl</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.66</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0369</td><td align="center" valign="middle" rowspan="1" colspan="1">MAP3K7 C-terminal-like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mill1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.78</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">MHC I-like leukocyte 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mrc1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0105</td><td align="center" valign="middle" rowspan="1" colspan="1">Mannose receptor, C type 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mtfp1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.33</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0250</td><td align="center" valign="middle" rowspan="1" colspan="1">Mitochondrial fission process 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mtus1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0077</td><td align="center" valign="middle" rowspan="1" colspan="1">Mitochondrial tumor suppressor 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mx2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.45</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">MX dynamin-like GTPase 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Myh11</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0483</td><td align="center" valign="middle" rowspan="1" colspan="1">Myosin heavy chain 11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Myo5b</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0261</td><td align="center" valign="middle" rowspan="1" colspan="1">Myosin Vb</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Myom2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.85</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53 &#215; 10<sup>&#8722;14</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Myomesin 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Nckap1l</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0091</td><td align="center" valign="middle" rowspan="1" colspan="1">NCK associated protein 1-like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Npas2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.43</td><td align="center" valign="middle" rowspan="1" colspan="1">1.51 &#215; 10<sup>&#8722;6</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Neuronal PAS domain protein 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Nrp2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0457</td><td align="center" valign="middle" rowspan="1" colspan="1">Neuropilin 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ntsr1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0405</td><td align="center" valign="middle" rowspan="1" colspan="1">Neurotensin receptor 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Nudt4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0073</td><td align="center" valign="middle" rowspan="1" colspan="1">Nudix hydrolase 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">P2rx4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0483</td><td align="center" valign="middle" rowspan="1" colspan="1">Purinergic receptor P2X 4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Paqr6</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0250</td><td align="center" valign="middle" rowspan="1" colspan="1">Progestin and adipoQ receptor family member 6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Per2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">1.29 &#215; 10<sup>&#8722;9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Period circadian regulator 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Per3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0226</td><td align="center" valign="middle" rowspan="1" colspan="1">Period circadian regulator 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Phlda1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.65</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0420</td><td align="center" valign="middle" rowspan="1" colspan="1">Pleckstrin homology-like domain, family A, member 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pi16</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.58</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0215</td><td align="center" valign="middle" rowspan="1" colspan="1">Peptidase inhibitor 16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pik3ip1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.43</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0043</td><td align="center" valign="middle" rowspan="1" colspan="1">Phosphoinositide-3-kinase interacting protein 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ppp1r14c</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0405</td><td align="center" valign="middle" rowspan="1" colspan="1">Protein phosphatase 1, regulatory (inhibitor) subunit 14c</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ppp1r3c</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0065</td><td align="center" valign="middle" rowspan="1" colspan="1">Protein phosphatase 1, regulatory subunit 3C</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rapgef5</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0451</td><td align="center" valign="middle" rowspan="1" colspan="1">Rap guanine nucleotide exchange factor (GEF) 5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rasd2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0091</td><td align="center" valign="middle" rowspan="1" colspan="1">RASD family, member 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rasl11b</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.59</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0105</td><td align="center" valign="middle" rowspan="1" colspan="1">RAS-like family 11 member B</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rcan1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.63</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005</td><td align="center" valign="middle" rowspan="1" colspan="1">Regulator of calcineurin 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rhobtb1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td><td align="center" valign="middle" rowspan="1" colspan="1">2.92 &#215; 10<sup>&#8722;9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Rho-related BTB domain-containing 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rhoj</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.41</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0210</td><td align="center" valign="middle" rowspan="1" colspan="1">Ras homolog family member J</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rimbp2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0025</td><td align="center" valign="middle" rowspan="1" colspan="1">RIMS-binding protein 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rpl3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0120</td><td align="center" valign="middle" rowspan="1" colspan="1">Ribosomal protein L3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Rpl3l</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.62</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0004</td><td align="center" valign="middle" rowspan="1" colspan="1">Ribosomal protein L3-like</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">S100a10</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.37</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0154</td><td align="center" valign="middle" rowspan="1" colspan="1">S100 calcium-binding protein A10</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">S100a4</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td><td align="center" valign="middle" rowspan="1" colspan="1">1.60 5</td><td align="center" valign="middle" rowspan="1" colspan="1">S100 calcium-binding protein A4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Slc38a2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td><td align="center" valign="middle" rowspan="1" colspan="1">Solute carrier family 38, member 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Slc41a3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">5.13 &#215; 10<sup>&#8722;7</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Solute carrier family 41, member 3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Slc8a2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.94</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0454</td><td align="center" valign="middle" rowspan="1" colspan="1">Solute carrier family 8 member A2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Smyd2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0483</td><td align="center" valign="middle" rowspan="1" colspan="1">SET and MYND domain-containing 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Sparcl1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.40</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td><td align="center" valign="middle" rowspan="1" colspan="1">SPARC-like 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Srebf1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.32</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0166</td><td align="center" valign="middle" rowspan="1" colspan="1">Sterol regulatory element-binding transcription factor 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Stxbp1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.34</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0038</td><td align="center" valign="middle" rowspan="1" colspan="1">Syntaxin-binding protein 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tef</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">TEF, PAR bZIP transcription factor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tf</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0295</td><td align="center" valign="middle" rowspan="1" colspan="1">Transferrin</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tfrc</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0142</td><td align="center" valign="middle" rowspan="1" colspan="1">Transferrin receptor</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tgm1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0084</td><td align="center" valign="middle" rowspan="1" colspan="1">Transglutaminase 1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tlr8</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0053</td><td align="center" valign="middle" rowspan="1" colspan="1">Toll-like receptor 8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tmem176b</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.31</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0197</td><td align="center" valign="middle" rowspan="1" colspan="1">Transmembrane protein 176B</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tmem179</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0091</td><td align="center" valign="middle" rowspan="1" colspan="1">Transmembrane protein 179</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tp53i11</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.42</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0051</td><td align="center" valign="middle" rowspan="1" colspan="1">Tumor protein p53 inducible protein 11</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tpsb2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.78</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0339</td><td align="center" valign="middle" rowspan="1" colspan="1">Tryptase &#946; 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Trim16</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.36</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0357</td><td align="center" valign="middle" rowspan="1" colspan="1">Tripartite motif-containing 16</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tspan18</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.57</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0084</td><td align="center" valign="middle" rowspan="1" colspan="1">Tetraspanin 18</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tut1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.51</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0277</td><td align="center" valign="middle" rowspan="1" colspan="1">Terminal uridylyl transferase 1, U6 snRNA-specific</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Tyrobp</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0365</td><td align="center" valign="middle" rowspan="1" colspan="1">Transmembrane immune signaling adaptor Tyrobp</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Ucp3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.69</td><td align="center" valign="middle" rowspan="1" colspan="1">4.13 &#215; 10<sup>&#8722;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">Uncoupling protein 3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Wee1</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.47</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0357</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEE1 G2 checkpoint kinase</td></tr></tbody></table></table-wrap><table-wrap position="float" id="genes-15-00975-t002" orientation="portrait"><object-id pub-id-type="pii">genes-15-00975-t002_Table 2</object-id><label>Table 2</label><caption><p>Top gene families represented within DEGs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of DEGs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene Symbol</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD molecules, C-type lectin domain family</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99 &#215; 10<sup>&#8722;8</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Mrc1</italic>, <italic toggle="yes">Pi16</italic>, <italic toggle="yes">Itga6</italic>, <italic toggle="yes">Itgam</italic>, <italic toggle="yes">Itgb2</italic>, <italic toggle="yes">Tlr8</italic>, <italic toggle="yes">Cd163</italic>, <italic toggle="yes">Tfrc</italic>, <italic toggle="yes">Cd93</italic>, <italic toggle="yes">Csf1r</italic>, <italic toggle="yes">Cd14</italic>, <italic toggle="yes">Fcgr2b</italic>, <italic toggle="yes">Cd44</italic>, <italic toggle="yes">Cd68</italic>, <italic toggle="yes">C5ar1</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD molecules, complement system, LY6/PLAUR domain-containing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.69 &#215; 10<sup>&#8722;7</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Itgam</italic>, <italic toggle="yes">Itgb2</italic>, <italic toggle="yes">C1qa</italic>, <italic toggle="yes">C1qb</italic>, <italic toggle="yes">C1qc</italic>, <italic toggle="yes">C5ar1</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Scavenger receptors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Mrc1</italic>, <italic toggle="yes">Cd163</italic>, <italic toggle="yes">Cd14</italic>, <italic toggle="yes">Cd68</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Basic helix&#8211;loop&#8211;helix proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0026</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Srebf1</italic>, <italic toggle="yes">Clock</italic>, <italic toggle="yes">Heyl</italic>, <italic toggle="yes">Bmal1</italic>, <italic toggle="yes">Npas2</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD molecules, protein phosphatase 1 regulatory subunits, integrin &#945; subunits</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0407</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Itga6</italic>, <italic toggle="yes">Itgam</italic></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rho family GTPases</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0407</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Rhoj</italic>, <italic toggle="yes">Rhobtb1</italic></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S100 calcium-binding proteins, EF-hand domain-containing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0407</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">S100a4</italic>, <italic toggle="yes">S100a10</italic></td></tr></tbody></table></table-wrap><table-wrap position="float" id="genes-15-00975-t003" orientation="portrait"><object-id pub-id-type="pii">genes-15-00975-t003_Table 3</object-id><label>Table 3</label><caption><p>Select human diseases associated with a subset of DEGs in this study. The last column indicates the number of DEGs that overlap with the known set of genes associated with human disease. Refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S3</xref> for full list. CVD: Cardiovascular disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Classification</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Disease</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDR</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of DEGs</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Libman&#8211;Sacks disease (nonbacterial thrombotic endocarditis)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0059</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Coronary restenosis (is_implicated_in)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0150</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Abdominal aortic aneurysm (is_marker_for)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0208</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Myocardial infarction (is_implicated_in)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0208</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Posterior choroidal artery infarction</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Peripheral arterial disease</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0330</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CVD</td><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension (is_implicated_in)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0336</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Immune disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">C1q deficiency</td><td align="center" valign="middle" rowspan="1" colspan="1">4.50 &#215; 10<sup>&#8722;5</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Immune disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Lupus erythematosus, systemic</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0013</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Immune disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Complement deficiency disease</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0125</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Immune disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Systemic lupus erythematosus (implicated_via_orthology)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0200</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Obesity</td><td align="center" valign="middle" rowspan="1" colspan="1">2.83 &#215; 10<sup>&#8722;9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">13</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Endogenous hyperinsulinism</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Exogenous hyperinsulinism</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Compensatory hyperinsulinemia</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Insulin resistance</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Insulin sensitivity</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Hyperinsulinism</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Metabolic syndrome</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0330</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Stroke, ischemic</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0078</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Ischemic stroke</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0078</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Brain ischemia (biomarker_via_orthology)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Cerebral infarction, left hemisphere</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Anterior choroidal artery infarction</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Cerebral infarction, right hemisphere</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Subcortical infarction</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neurovascular disease</td><td align="center" valign="middle" rowspan="1" colspan="1">Cerebral infarction</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Myeloid leukemia, chronic</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Acute myeloid leukemia, m1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0014</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Acute myeloid leukemia (aml-m2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0014</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Leukemia, myelocytic, acute</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0057</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Adult t-cell leukemia/lymphoma (is_marker_for)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0181</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Acute promyelocytic leukemia</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0218</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cancer, hematological</td><td align="center" valign="middle" rowspan="1" colspan="1">Hematologic neoplasms</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0258</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sleeping disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Seasonal affective disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sleeping disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">Advanced sleep phase syndrome, familial</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0042</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleeping disorder</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced sleep phase syndrome (is_implicated_in)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0059</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td></tr></tbody></table></table-wrap><table-wrap position="float" id="genes-15-00975-t004" orientation="portrait"><object-id pub-id-type="pii">genes-15-00975-t004_Table 4</object-id><label>Table 4</label><caption><p>Select pharmacologicals associated with a subset of DEGs in this study. The list contains current and discontinued drugs. Refer to <xref rid="app1-genes-15-00975" ref-type="app">Table S4</xref> for the full list of pharmacologicals and associated DEGs. CVD: cardiovascular disease, HIV: human immunodeficiency virus, MS: multiple sclerosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Use</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of DEGs</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDR</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Atorvastatin calcium</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-CVD, antihypercholesterolemic</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0069</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cerivastatin</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-CVD, antihypercholesterolemic</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0371</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Simvastatin</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-CVD, antihypercholesterolemic</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0007</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Abciximab</td><td align="center" valign="middle" rowspan="1" colspan="1">Antithrombotic</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Losartan</td><td align="center" valign="middle" rowspan="1" colspan="1">Antihypertensive, angiotensin receptor blocker</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0190</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Valsartan</td><td align="center" valign="middle" rowspan="1" colspan="1">Antihypertensive, angiotensin receptor blocker</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0051</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hydrochlorothiazide</td><td align="center" valign="middle" rowspan="1" colspan="1">Antihypertensive, diuretic</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0305</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Isoproterenol</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-bradycardia, non-selective &#946;-adrenergic receptor agonist</td><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">1.043 &#215; 10<sup>&#8722;6</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Muraglitazar</td><td align="center" valign="middle" rowspan="1" colspan="1">Antidiabetic</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0037</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rosiglitazone</td><td align="center" valign="middle" rowspan="1" colspan="1">Antidiabetic</td><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">3.669 &#215; 10<sup>&#8722;5</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tesaglitazar</td><td align="center" valign="middle" rowspan="1" colspan="1">Antidiabetic</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0025</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Troglitazone</td><td align="center" valign="middle" rowspan="1" colspan="1">Antidiabetic</td><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0305</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Basiliximab</td><td align="center" valign="middle" rowspan="1" colspan="1">Immune suppressor, organ transplant</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Muromonab</td><td align="center" valign="middle" rowspan="1" colspan="1">Immune suppressor, organ transplant</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Efalizumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-auto immune disease, anti-psoriasis</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Etanercept</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-auto immune disease, anti-psoriasis</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alefacept</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-auto immune disease, psoriasis</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rituximab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-Rheumatoid arthritis</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adalimumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-rheumatoid arthritis, anti-Crohn&#8217;s disease, anti-psoriasis</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Palivizumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Antiviral</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">9.213 &#215; 10<sup>&#8722;5</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nevirapine</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-HIV</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0246</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Daclizumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Natalizumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-MS</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Apomab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0048</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bevacizumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cetuximab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ibritumomab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">temozolomide</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer, brain</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0414</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Trastuzumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer, breast</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Alemtuzumab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer, leukemia</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dasatinib</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer, leukemia</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0018</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Doxorubicin</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer, leukemia</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">9.174 &#215; 10<sup>&#8722;7</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gemtuzumab ozogamicin</td><td align="center" valign="middle" rowspan="1" colspan="1">Anticancer, leukemia</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Tositumomab</td><td align="center" valign="middle" rowspan="1" colspan="1">Anti-non-Hodgkins lymphoma</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clodronate</td><td align="center" valign="middle" rowspan="1" colspan="1">Antiosteoporotic</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0039</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Raloxifene Hydrochloride</td><td align="center" valign="middle" rowspan="1" colspan="1">Antiosteoporotic</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0305</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Zoledronic acid</td><td align="center" valign="middle" rowspan="1" colspan="1">Antiosteoporotic</td><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0198</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melatonin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleeping aid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.279 &#215; 10<sup>&#8722;5</sup></td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>